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High Molecular Weight Isoforms of FGF2 Contribute to Osteoarthritis by FGF23 mediated
Wnt/β-catenin Signaling
Patience Meo Burt, PhD
University of Connecticut, 2018
Osteoarthritis (OA) the most common degenerative joint disease, characterized by
articular cartilage degradation, has no cure and molecular mechanisms which cause the disease
remain largely unknown. Although fibroblast growth factor 2 (FGF2) has been implicated in OA
pathogenesis, previous findings showed contrasting roles and never examined if/how the varying
isoforms (high molecular weight, HMW, or low molecular weight, LMW), in which the FGF2
gene encodes, contribute to the disease. Clearly, there is a need to further understand the
involvement of FGF2 isoforms in OA pathophysiology, which is the purpose of this research
study.
Using novel mouse models in which HMW or LMW FGF2 isoforms have been ablated
(Fgf2HMWKO and Fgf2LMWKO mice) or overexpressed (HMWTg or LMWTg mice) we explored the
role the isoforms play in OA. HMWTg mice phenocopy most traits in humans with X-linked
hypophosphatemic rickets (XLH) and its murine homologue, the Hyp mouse, including
increased FGF23 levels. Subjects with XLH and Hyp mice develop osteoarthropathy, and Hyp
mice overexpress HMW FGF2 isoforms, which co-localized with FGF23 in HMWTg mice.
There is crosstalk between FGF23 and Wnt/β-catenin signaling, both catabolic regulators in OA,
and both upregulated in Hyp mice. Thus, we hypothesized that mice overexpressing HMW FGF2
isoforms will develop OA, due to increased FGF23 that is propating the canonical Wnt signaling
cascade. Mice only expressing HMW FGF2 isoform (Fgf2LMWKO mice) will develop OA, unlike
mice only expressing LMW FGF2 (Fgf2HMWKO mice).
We assessed for signs of OA in these FGF2 isoform transgenic and knockout mice and
found that HMWTg and Fgf2LMWKO mice had loss of articular cartilage, increased OA markers,
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abnormal subchondral bone structures, and increased FGF23/FGFR1 expression as indicated by
radiography/microCT, histology, and qPCR analyses. HMWTg chondrocytes had increased
expression of canonical Wnt signaling components, FGF23, and OA markers which were
rescued after inhibition of Wnt as indicated by histology, qPCR, and Western blot analyses. OA
was partially attenuated in HMWTg mice after neutralizing FGF23Ab treatment.
Thus, HMW FGF2 modulates FGF23/FGFR1/Wnt/β-catenin signaling-mediated OA in
chondrocytes, offering new insight into FGF2 and OA pathogenesis and a potential pathway to
target in the future treatment of the disease.
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Chapter 1
Introduction
1.1 Osteoarthritis
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of
chronic disability worldwide, as it affects over 27 million adults in the United States alone (1).
OA is primarily present in the knee and was long thought to be caused by the wearing away of
the articular cartilage surface, however the Osteoarthritis Research Society International
(OARSI) has recently redefined the disease as a disorder of the entire joint to include not only
degradation of cartilage, but abnormal remodeling of the subchondral bone and inflammation of
the meniscus/synovium due to overall abnormal joint tissue metabolism (1,2). Specifically,
hallmarks of OA include bone spur or osteophyte formation (3), dynamic alterations of
trabecular architecture of the subchondral bone characterized by the thinning of underlying bone
in early stages of OA disease due to increased bone resorption with subsequent sclerosis of bone
in later stages (4), and vascular invasion/angiogenesis in the typically avascular cartilage tissue
(5). In addition to loss of articular cartilage, there is a shift in the normally quiescent
chondrocytes in which homeostasis is unable to be maintained, and the excessive catabolic
activity results in increased production of degradative enzymes, a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS) and matrix metalloproteinases
(MMPs), and chondrocyte dedifferentiation and hypertrophy (6-9).
The complexity of OA is only further enhanced due to the plethora of genetic and
acquired factors, such as age and obesity, and biochemical and biophysical factors, such as
proinflammatory cytokines and injury/instability, which contribute to the pathophysiology of the
disease. This pathogenesis of OA activates various biochemical pathways, often in chondrocytes,
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leading to an imbalance of anabolic and catabolic factors (6). The signaling pathways implicated
in OA pathogeny are abundant and the molecular mechanisms underlying the disease are not
fully understood. Thus, there is a critical need for additional studies to elucidate such
mechanisms in order to develop therapeutic targets for the treatment of OA, as there are no
current effective treatment options beyond total joint replacement (10).

1.2 Mouse Models Used to Study OA
Although there are no disease modifying drugs to prevent or treat OA, there have been
numerous animal studies dedicated to further understanding its initiation, development, and
potential inhibition in an effort to find a treatment. As mentioned above, there are many
molecular pathways involved in the maintenance of cartilage homeostasis and
experimental/genetic modulation of these signaling pathways in murine models is used to study
OA. Frequently, “knockout” (KO) mouse models are used in which the gene of interest has been
systemically or tissue-specifically deleted and mice will spontaneously develop OA with age.
For example, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), which is a necessary inhibitor of
cartilage degradation by MMPs, when deleted in mice, results in changes similarly seen in
humans with OA (11). Conversely, transgenic mouse models that overexpress the gene of
interest can be used to study the involvement of various pathways in OA, such as mice that
overexpress human MMP13 in articular chondrocytes which have severe joint destruction (7).
Articular chondrocytes isolated from mice have been a useful way to study these pathways, too
(12,13). In addition to spontaneous OA, post-traumatic OA can be induced in mice, using either
control or genetically modified strains, through surgical procedures, such as destabilization of the
medial meniscus (DMM) (14) or chemical manipulations, such as intra-articular injection of
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collagenase, an enzyme that degrades the cartilage matrix (15). Recently, a more novel,
noninvasive approach has been used in which mice undergo mechanical tibial compression
loading (16). Despite these various models used to examine OA there still remains a need to
identify catabolic players involved and continue to clarify the mechanism by which previously
recognized signals contribute to the disease.

1.3 FGF2, Focusing on its Role in OA
While numerous signaling factors participate in OA pathogenesis, the fibroblast growth
factor (FGF) family, particularly FGF2, has received considerable attention in its regulation of
cartilage and joint homeostasis (17,18). Though FGF2 is expressed by many different cell types
and regulates cell growth, migration, differentiation, and survival during development, it is
crucial for bone growth and cartilage metabolism (19) and is expressed by osteoblasts and
chondrocytes (20). However, there is conflicting evidence supporting both the catabolic and
anabolic potential of FGF2 within the joint. Specifically, exogenous FGF2 simulates MMP-13
and ADAMTS-5 production in articular cartilage explants in vitro (17,21) and the level of FGF2
in OA synovial fluid is nearly twice that of healthy knees (18), suggesting catabolic functions.
Also, FGF2 gene and protein expression was increased in human OA subchondral sclerotic
osteoblasts (22). Alternatively, intra-articular injection of total FGF2 reversed OA progression in
a surgically-induced OA mouse model (23) and Fgf2 knockout (Fgf2ALLKO) mice develop
accelerated spontaneous and surgically-induced OA (24), signifying an anabolic role of FGF2.
These contradictory results may be due to the binding affinity of FGF2 for FGFR1 and
FGFR3, which have contrasting roles in cartilage homeostasis. FGFR1 is elevated in human OA
chondrocytes, promotes cartilage destruction (25), and its inhibition attenuates OA in murine
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cartilage (26), while FGFR3 is reduced in human OA chondrocytes (25), drives anabolic activity
in cartilage (27), and its deficiency accelerates murine OA (28).

1.4 Isoforms of FGF2 in bone and its Mouse Models
Interestingly, FGF2 can be produced as distinct isoforms by alternative initiation of
translation from a single mRNA, as it encodes for multiple protein isoforms including the high
molecular weight (HMW) isoforms and the low molecular weight (LMW) isoform, which are
ubiquitously expressed in cells, including osteoblasts. The LMW isoform is translated from the
traditional AUG start codon, while the HMW isoforms are initiated upstream of the LMW start
site from individual nonconventional CUG codons. Humans have three HMW FGF2 isoforms
(22, 22.5, 24kDa), while rodents have two HMW FGF2 isoforms (21, 22kDa). The HMW FGF2
isoforms contain a nuclear localization sequence, enabling the protein to function as an intracrine
factor. Humans and rodents also have one LMW FGF2 isoform, which is transported out of the
cell, acting as a conventional growth factor and functioning in an autocrine/paracrine fashion
(29-31). It should be noted that there is evidence suggesting the capability of HMW FGF2
having paracrine and/or autocrine activity, as it was shown to be exported from cardiac nonmyocytes (32).
Mouse models in which the isoforms have been selectively deleted or overexpressed have
been developed and studied, particularly in the context of skeletal biology, but never utilized to
examine OA. Mice constitutively deficient in LMW FGF2, Fgf2LMWKO mice, were previously
created and characterized (33) and of importance, had decreased bone mineral density (BMD)
compared to WT mice (34), a trait also observed in mice with a full-length deletion of FGF2
(Fgf2ALLKO mice) (35). In a comparable manner mice lacking HMW FGF2, Fgf2HMWKO mice
were generated and characterized (36) and found to have increased BMD (37). Our lab generated
4

mice that overexpress LMW FGF2 in osteoblastic lineage cells, using a Col3.6 promoter,
(LMWTg mice) and found an increase in bone mass and BMD (34). We similarly developed
mice that overexpress HMW FGF2, using a Col3.6 promoter (HMWTg mice) which were found
to have decreased BMD, dwarfism, rickets, osteomalacia, hypophosphatemia, and increased
FGF23 in bone. These are all traits in which the HMWTg mice phenocopy humans with Xlinked hypophosphatemia (XLH) (38).

1.5 XLH and FGF23
XLH is the most common form of inherited vitamin D-resistant rickets, affecting 1 in
20,000 people, and leads to renal phosphate wasting, inappropriately high levels of circulating
FGF23, growth retardation, osteomalacia, rickets, and osteoarthropathies (39). Joint pain is the
most common symptom in adults, which can be attributed to the development of enthesopathy
(mineralization of the tendon and ligament insertion sites) and OA, hallmarks of XLH, and
include thinning of articular cartilage and sclerosis of subchondral bone (40, 41). Just as our
HMWTg mice phenocopy XLH, so does the Hyp mouse, the murine homologue to XLH, which
has a deletion in the Phex gene and is known to develop the same characteristic traits of humans
with XLH, including hypophosphatemia and elevated FGF23 levels (42). Also, enthesopathy and
osteophyte formation were observed in Hyp mice (43). Other signs of degenerative joint disease
were prominent in these mice including, decreased articular cartilage thickness, increased
chondrocyte alkaline phosphatase activity, defective mineralization, and angiogenesis of the
cartilage (44). While osteoarthropathy is present in both humans with XLH and Hyp mice, this
was not previously examined in our HMWTg mice and the mechanism responsible for the
observed joint degeneration was unknown.
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We have previously shown that the traits in which HMWTg mice phenocopy Hyp mice
include dwarfism, decreased BMD, rickets, osteomalacia, hypophosphatemia, and increased
levels of FGF23, in serum and bone. Also, Hyp mice overexpress FGF2 HMW isoforms. Also,
we reported that HMW FGF2 modulates and co-localizes with FGF23 in HMWTg mice (38).
There is a great deal of evidence implicating the destructive role FGF23 has in cartilage and joint
homeostasis, as FGF23 has been found to be upregulated in human OA chondrocytes (45) and
exogenous FGF23 expression stimulates hypertrophy and increases FGFR1 production in
chondrocytes (46,47). Thus, increased HMW FGF2 may be responsible for elevated FGF23
levels, which is causing the OA phenotype.

1.6 Wnt Signaling, Focusing on its Role in OA
The Wnt/β-catenin signaling pathway regulates cell migration, differentiation, and
proliferation and is essential for cartilage development and homeostasis (48,49). Wnt ligands,
cysteine-rich glycoproteins, initiate downstream signaling by binding to either low-density
lipoprotein-related receptor (LRP) 5 or 6 facilitating interaction with Axin2, a component of the
multi-protein β-catenin destruction complex which includes glycogen synthase kinase (GSK) 3,
allowing stabilization, accumulation, and translocation of β-catenin to the nucleus where it
complexes with T cell factor/Lymphoid-Enhancing Factor (Tcf/Lef) to modulate transcription of
various target genes (48). Although aberrant noncanonical Wnt signaling can impact cartilage
(49,50), there is a wide variety of literature recognizing the tremendous importance of canonical
Wnt/β-catenin signaling (51-58). Particularly, excessive canonical Wnt signaling has been shown
to negatively impact cartilage, as observed by an upregulation in Wnt7b, Wnt16, LRP5, and
nuclear β-catenin expression in OA cartilage (53-56). Mice deficient in LRP5 were protected
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from experimental OA and LRP5 was determined to be responsible for Wnt-induced cartilage
destruction by regulating production of MMPs (53). Also, it was found that increased Sclerostin
(Sost) and Dickkopf WNT Signaling Pathway Inhibitor (Dkk1) levels (Wnt inhibitors) protect
against cartilage degradation in OA in mice (57,58).
It has been well established that FGF23 stimulates hypertrophy due to signaling through
FGFR1 (46,47), and FGFR signaling was found to increase Wnt/β-catenin signaling in
chondrocytes (59). Also, FGF signaling can elevate nuclear -catenin levels through inactivating
GSK3 (60), and Wnt/-catenin activity can stimulate FGF23 promoter activity in osteoblasts
(63). Additionally, Wnt signaling components are enhanced in Hyp mice (61, 62), which have
increased levels of FGF23 and develop osteoarthropathy (38,43,61). Together these studies
imply that FGF23 and canonical Wnt signaling cooperatively may be contributing to OA.

1.7 Specific Aims
As previously discussed, OA is a complex and disabling joint disease, characterized
mainly by articular cartilage degradation, and affects tens of millions of people (1), costing the
US economy over $86 billion dollars a year (63). Beyond total joint replacement surgery there is
no effective treatment option (10), so there is a critical need to elucidate the molecular
mechanism responsible for OA in order to identify therapeutic targets to treat the disease, which
is the purpose of this research project.
Although many biochemical pathways are implicated in OA pathogenesis, FGF2 and FGF
signaling are known to be important in cartilage homeostasis and degradation, with some studies
recognizing FGF2 as catabolic and others regarding FGF2 is chondroprotective (17,18,21-23).
These conflicting reports indicate that a more comprehensive analysis is required to further
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understand its specific mechanism(s). Though the high molecular weight (HMW) and low
molecular weight (LMW) isoforms in which the FGF2 gene encodes, have been studied in bone
(37,34), their impact on joint and cartilage was never examined. We explore the role that the
individual FGF2 isoforms play in OA using mouse models, in which either HMW or LMW
FGF2 isoforms have been ablated (Fgf2HMWKO and Fgf2LMWKO mice) or overexpressed (HMWTg
or LMWTg mice). Importantly, HMWTg mice phenocopy most traits in humans with XLH and
its murine homologue, the Hyp mouse, including increased FGF23 in serum and bone (38,42).
Subjects with XLH and Hyp mice also develop degenerative joint disease (39,43,44), and Hyp
mice overexpress HMW FGF2 isoforms, which was found to co-localize with FGF23 in
HMWTg mice (38). FGF23 negatively impacts cartilage via FGFR1 (46,47), and FGFR
signaling was found to increase Wnt/β-catenin signaling in chondrocytes (59), a pathway known
to contribute to OA (48,49), which is also upregulated in some tissues of the Hyp mouse (61,62).
Again, HMWTg mice phenocopy subjects with XLH and Hyp mice (known to have increased
HMW FGF2 associated with enhanced FGF23 expression and activated canonical Wnt
signaling).
Since both XLH subjects and Hyp mice develop OA, the central hypotheses are: i) Mice
overexpressing HMW FGF2 isoforms, in which FGF23 is increased, will develop more severe
OA signs than Vector control mice. ii) Fgf2LMWKO mice (which only express the HMW FGF2
isoform) will be more likely to develop OA compared to the wild-type, whereas, the Fgf2HMWKO
mice will not develop OA as frequently or severely as the wild-type. iii) The HMW FGF2
isoforms cause upregulation of FGF23, which binds to FGFR1 propagating the canonical Wnt
signaling cascade, promoting an OA phenotype. These hypotheses will be tested through the
following aims:
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Aim 1: Determine if overexpression of HMWFGF2 isoforms leads to severe OA.
1A) Characterize the OA phenotype in HMWTg mice.
1B) Characterize FGF and FGFR signaling in HMWTg knee joints.
Rationale/hypothesis: Since HMWTg mice phenocopy subjects with XLH and Hyp mice, which
are shown to develop OA, the hypothesis is that HMWTg mice will develop more severe signs of
OA compared to the Vector control. Also, FGF2, FGF23, FGFR1, and FGFR3 expression is
known to be modulated in OA, therefore we posit that HMWTg mice will have altered
expression levels within the joint, particularly an increase in FGF23.
In order to assess for signs of degenerative joint disease in HMWTg and Vector mice
radiographic imaging, microCT analysis, histological methods (immunohistochemistry, SafraninO/von Kossa/alkaline phosphatase staining) and qPCR analysis of RNA extracted from whole
knee joints will be used. These methods will identify any abnormalities in the subchondral bone,
loss of proteoglycan content and articular cartilage integrity, and increases in matrix
metalloproteinases/genes implicated in OA (degradative enzymes such as MMP13, Adamts5,
etc.), in knees of 2, 8, and 18-month-old HMWTg and Vector control mice and also compared to
LMWTg mice. Immunohistochemistry and qPCR analysis will be used to examine FGF and
FGFR expression.

Aim 2: Examine the role of selective deletion of HMWFGF2 isoforms and LMWFGF2
isoform in the development of OA.
Rationale/hypothesis: Since deletion of total FGF2 causes OA in mice, we want to examine
whether selectively deleting either the LMW or HMW isoform of FGF2 will cause an OA
phenotype. The hypothesis is that Fgf2LMWKO mice that only express the HMW FGF2 isoforms
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(which are increased in Hyp mice that develop OA), will be more likely to develop OA
compared to the wild-type, similar to that observed in Fgf2ALLKO, whereas, the Fgf2HMWKO mice
will not develop OA as frequently or severely as their wild-type littermate control, as these mice
do not possess the HMW FGF2 isoforms.
In order to assess for signs of spontaneous OA the techniques proposed in Aim 1 will be
employed for knee joints from 2, 6, and 9-month-old male Fgf2ALLKO, Fgf2HMWKO, and
Fgf2LMWKO, and their WT littermates. We will also use another OA model, involving tibial
compression loading, in order to determine if it further accelerates OA in mice or if mice are
protected from OA induction. .

Aim 3: Determine if HMW FGF2 isoform contributes to OA via modulation of
FGF23/FGFR1 and canonical Wnt signaling cascade.
Rationale/hypothesis: Given the crosstalk and involvement in cartilage degradation between
FGF23-Wnt/β-catenin signaling and the upregulation of both FGF23 and active β-catenin in Hyp
mice, which also overexpress HMW FGF2 and develop OA, we will determine if HMWTg
cartilage has increased Wnt components resulting in OA. The hypothesis is that OA may be
caused by the overabundance of FGF23, which binds to FGFR1, activating canonical Wnt/βcatenin signaling leading to an increase in degradative enzymes/hypertrophy.
In vivo studies-In order to determine if components of the Wnt signaling pathway are
increased in HMWTg knees compared to Vector, qPCR analysis will be used following RNA
extraction from whole joints and immunohistochemistry used to examine protein expression and
location. Also, HMWTg (and Vector) mice will be treated with an FGF23 neutralizing antibody
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in vivo to determine if blocking of FGF23 inhibits FGFR1 signaling/OA marker gene expression,
and if the OA phenotype is attenuated in HMWTg mice.
In vitro studies- In order to determine if FGF23-Wnt signaling and OA marker
expression is enhanced in HMWTg chondrocytes, primary chondrocytes will be harvested and
cultured from HMWTg mice and compared to those from Vector and LMWTg mice.
Gene/protein expression of Wnt signaling components/OA markers will be examined by qPCR
and Western blot analyses. Alcian blue and alkaline phosphatase staining will be used to
determine if HMWTg chondrocytes appear to be more hypertrophic/osteoarthritic. In order to
characterize the molecular mechanism, cultures will be treated with a potent canonical Wnt
inhibitor to determine if the factors downstream of the inhibitor are decreased and OA marker
expression is reduced.
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Chapter 2
FGF2 High Molecular Weight Isoforms Contribute to Osteoarthropathy in Male Mice
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2.1 Abstract
Humans with X-linked hypophosphatemia (XLH) and Hyp mice, the murine homologue
of the disease, develop severe osteoarthropathy and the precise factors that contribute to this joint
degeneration remain largely unknown. Fibroblast growth factor 2 (FGF2) is a key regulatory
growth factor in osteoarthritis. Although there are multiple FGF2 isoforms the potential
involvement of specific FGF2 isoforms in joint degradation has not been investigated. Mice that
overexpress the high molecular weight FGF2 isoforms in bone (HMWTg mice) phenocopy Hyp
mice and XLH subjects and Hyp mice overexpress the HMWFGF2 isoforms in osteoblasts and
osteocytes. Since Hyp mice and XLH subjects develop osteoarthropathies we examined whether
HMWTg mice also develop knee joint degeneration at 2, 8, and 18-month-old compared with
VectorTg (control) mice. HMWTg mice developed spontaneous osteoarthropathy as early as 2
months of age with thinning of subchondral bone, osteophyte formation, decreased articular
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cartilage thickness, abnormal mineralization within the joint, increased cartilage degradative
enzymes, hypertrophic markers, and angiogenesis. FGF receptors 1 and 3 and fibroblast growth
factor 23 were significantly altered compared to VectorTg mice. In addition, gene expression of
growth factors and cytokines including bone morphogenetic proteins, Insulin like growth factor
1, Interleukin 1 beta, as well transcription factors Sex determining region Y box 9, hypoxia
inducible factor 1 and nuclear factor kappa B subunit 1 were differentially modulated in
HMWTg compared with VectorTg. This study demonstrates that overexpression of the HMW
isoforms of FGF2 in bone results in catabolic activity in joint cartilage and bone that leads to
osteoarthropathy.

2.2 Introduction
X-linked hypophosphatemia (XLH), the most common form of inherited vitamin D-resistant
rickets, which affects 1 in 20,000 people, leads to renal phosphate wasting, inappropriately high
levels of circulating fibroblast growth factor 23 (FGF23), rickets, growth retardation,
osteomalacia, and osteoarthropathies (39). The most common symptom in adults is joint pain,
which can be attributed to the development of enthesopathy and osteoarthritis, both hallmarks of
XLH, which include thinning of articular cartilage and sclerosis of subchondral bone (40, 41).
The Hyp mouse, a murine homologue of XLH is known to develop the same signs of humans
with XLH, including hypophosphatemia and elevated levels of FGF23 (42). More recently, the
Hyp mouse was found to develop enthesopathy, which included mineralization of the tendon and
ligament insertion sites, as well as, osteophyte formation (43). Degenerative osteoarthropathy
was also prominent in these mice, which was characterized by decreased articular cartilage
thickness, increased chondrocyte alkaline phosphatase activity, defective mineralization, and
vascular invasion of the cartilage (44).
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We have previously developed transgenic mice that phenocopy the Hyp mouse and
subjects with XLH, by overexpressing the high molecular weight isoforms (HMW) of fibroblast
growth factor 2 (FGF2) under a Col3.6 promoter (HMWTg mice) (38). The FGF2 gene encodes
multiple protein isoforms with varying molecular weights. Humans have three HMW FGF2
isoforms (22, 22.5, 24kDa), and rodents have two HMW FGF2 isoforms (21, 22kDa). These
HMW FGF2 isoforms possess a nuclear localization sequence that enables the proteins to
function in an intracrine manner. Humans and rodents also have one low molecular weight
(LMW) FGF2 isoform that is exported from cells which functions in an autocrine and/or
paracrine manner (30, 31). The bone phenotype of HMWTg mice was previously fully
characterized and it was also determined that HMWTg mice develop dwarfism, decreased bone
mineral density, rickets, osteomalacia, and hypophosphatemia, and display increased FGF23, in
serum and bone, which are the traits in which the HMWTg mice phenocopy Hyp mice (38).
Also, Hyp mice were previously reported to overexpress the HMW FGF2 isoforms (38). Since
the Hyp mouse, as well as, humans with XLH develop osteoarthropathies (40, 44) the aim of our
study was to determine if HMWTg mice also develop joint degeneration.
This study is of particular importance since recently FGF2 has received considerable
attention in the regulation of cartilage and joint homeostasis (18, 24). There is conflicting
evidence that demonstrates both catabolic and anabolic potential of FGF2 in the joint
(17,18,21,24) and no studies, as of yet, addressed the specific FGF2 isoforms in the development
of osteoarthropathy.
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2.3 Materials and Methods

2.3.1. Experimental Animals
All animal protocols were approved by the UConn Health Institute of Animal Care and Use
Committee. We have previously described in detail the generation of HMWTg and
control/vector transgenic mice (VectorTg) (38). Briefly, the Col3.6-HMW-IRES-green
fluorescent protein-sapphire (GFPsaph) construct was created by inserting HMW isoforms of
human Fgf2 (22, 23, and 24 kDa) cDNA in previously made Col3.6-CAT-IRES-GFPsaph in
place of a chloramphenicol acetyltransferase fragment. This expression construct is able to
concurrently overexpress HMW and GFPsaph from a single bicistronic mRNA. The Col3.6IRES/GFPsaph (Vector), which overexpresses the transgene cassette without the additional
FGF2 coding sequences, was created as a control. Col3.6-CAT-IRES-GFPsaph or Col3.6IRES/GFPsaph construct inserts were released via digestion by AseI and AflII. The Gene
Targeting and Transgenic Facility at UCONN Health performed microinjections in the pronuclei
of fertilized oocytes. The individual transgenic mouse lines were established by breeding founder
mice of the F2 generation of the FVBN strain with wild-type mice. Male homozygous VectorTg
and HMWTg mice at 2 (n=10-11/group), 8 (n=7-8/group), and 18 (n=4-7/group) months of age
were used in this study. We utilized two independent lines of HMWTg mice, Line 203 (for 2 and
8-month-old mice) and Line 204 (for 18-month-old mice), which were previously extensively
characterized (38). Male homozygous mice that overexpress the human low molecular weight,
18-kDa isoform, of FGF2 (LMWTg mice) were created in a similar manner as described above
(34) and were compared to the VectorTg controls at 19 months of age (n=4/group) for
development of osteoarthropathy.
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2.3.2. Radiology and Micro-computed tomography
Digital radiographs of murine knee joints were obtained with a SYSTEM MX 20 from Faxitron
X-ray Corporation. Imaging of left knee architecture was performed using ex vivo microcomputed tomography (μCT40, ScanCo Medical AG, Bassersdorf, Switzerland). The region of
subchondral trabecular bone of the epiphysis in the femur and tibia were analyzed by 3dimensional μCT for the following morphometric parameters: bone volume/tissue volume
(BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular number
(Tb.N).

2.3.3. Histology
Whole knee joints were dissected and fixed in 4% paraformaldehyde for 6 days followed by
decalcification with 14% EDTA solution. Specimens were processed for paraffin embedding in a
frontal orientation and 7-μm alternate sections were obtained. After sections were deparaffinized and rehydrated, Safranin-O staining of glycosaminoglycans was performed using
0.1% aqueous Safranin-O, followed by counter-staining using Weigert’s Iron Hematoxylin and
0.02% aqueous Fast Green. For alkaline phosphatase and von Kossa staining, the knees were
formalin fixed, cryomatrix (Thermo Electron Corp., Pittsburgh, PA) embedded, and sectioned at
6-μm. Alkaline phosphatase staining was done by incubating tissue with 100mM Tris-HCl buffer
(pH 8.2) for 10 minutes, followed by incubation with Vector Blue Alkaline Phosphatase
Substrate (Vector Laboratories, Burlingame, CA, USA) for 30 minutes.

2.3.4. Immunohistochemistry and RNAscope
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Immunohistochemical staining was performed using ImmunoCruz™ ABC Staining System
(Santa Cruz Biotechnology, CA, USA) and DAB Peroxidase Substrate kit (Vector Laboratories,
Burlingame, CA, USA). Following de-paraffinization and rehydration, sections were incubated
at 95°C with 10mM sodium citrate buffer for 10 minutes for antigen retrieval. Once cooled to
room temperature for 30 minutes, 3% hydrogen peroxide in water was added to the sections for
15 minutes. After blocking with 10% serum for one hour, the slides were incubated with primary
antibodies in blocking buffer overnight at 4°C. Details of the following primary antibodies are in
Table 1: rabbit anti-MMP13 (Abcam), rabbit anti-ADAMTS5 (Abcam), rabbit anti-FGF-2 (Santa
Cruz), rabbit anti-FGFR-1 (Santa Cruz), rabbit anti-FGFR-3 (Santa Cruz), rabbit anti-VEGF
(Santa Cruz), anti-FGF-23 (R & D Systems, MN, USA), rabbit anti-NF-kB p65 (Abcam), and
anti-rabbit SOX9 (Abcam). Slides were then washed with TBS containing 0.1% Tween 20 and
incubated with the appropriate 1:200 biotinylated secondary antibody at room temperature for 30
minutes. Next, slides were washed and developed with DAB substrate solution, followed by
counterstaining with Harris hematoxylin. RNAscope was performed using Formalin-Fixed
Paraffin-Embedded Sample Preparation and Pretreatment, RNAscope® 2.5 HD Detection
Reagent, and the probe for mouse Col10a1 according to the manufacturer’s instructions
(Advanced Cell Diagnostics, Newark, CA).

2.3.5. RNA isolation and real time PCR
Following skin and bulk muscle removal from 2-month-old VectorTg and HMWTg mice, total
RNA was extracted from whole joints including all structures of the joint, above the growth
plate, using TRIzol reagent (34). RNA was reverse-transcribed to cDNA using RNA to cDNA
EcoDry Premix kit (Clontech Inc., A Takara Bio Company). For real time quantitative reverse
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transcription-PCR (qPCR) analysis a Bio-Rad MyiQ system was used with iTaqTM Universal
SYBR Green Supermix (Bio-Rad, CA, USA). The primers used for real-time PCR (Table 2)
were synthesized by IDT (Integrated DNA Technologies, Inc., CA). The relative change in
mRNA was normalized to the housekeeping gene Beta-actin (β-actin) which served as an
internal reference for each sample. For each group the mRNA level is expressed as the fold
change relative to the first sample.

2.3.6. Determination of articular cartilage thickness
Articular cartilage thickness was determined based on a method previously reported (64) by
using Safranin-O stained sections and measuring the mean distance at the thickest point from the
articular cartilage surface to the subchondral bone interface across three points per section using
ImageJ. Images were taken at 20x from three separate representative sections from each knee,
closest to the center of the joint, from different VectorTg and HMWTg mice (n=3-4/group).

2.3.7. Statistical analysis
Results are presented as means ± S.D. Student’s t-test was used to analyze differences between
groups. Differences were considered significant at p values less than 0.05, unless otherwise
stated.

2.4 Results
2.4.1. Time course of radiological and morphometric changes in VectorTg and HMWTg knee
joints
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Digital radiographs were assessed for indications of OA in the bone of VectorTg and HMWTg at
2, 8, and 18 months of age (Fig. 1A). All (11 out of 11) knee joints of HMWTg mice at 2 months
of age showed flattening of the tibial plateau and thinning of femoral subchondral bone.
Additionally, the knee joints of all (8 out of 8) HMWTg mice at 8 months old displayed thinning
of subchondral bone, as well as, osteophyte formation mainly on the posterior tibiae. Joint
destruction was apparent in 18-month-old HMWTg mice, characterized by osteophyte formation,
sclerotic bone development, and narrowing of the patellofemoral space (7 out of 7). Conversely,
radiographs of VectorTg mice did not display evidence of skeletal joint deterioration at any age.
Micro-CT images of HMWTg knees showed thinning of the subchondral bone of the
femur and tibia along with greater loss of trabeculae compared to VectorTg at 2 and 8 months of
age (Fig. 1B). By 18 months of age, evidence of severe OA was noted in HMWTg knees, which
included sclerosis of the femur. Also, three-dimensional (3D) surface renderings of HMWTg
knees showed pitting, erosion, and deterioration, which increased in intensity with age, while the
VectorTg subchondral plate retained smooth contour and joint integrity. 3D morphometric
parameters calculated from micro-CT results of the epiphysis of HMWTg femurs and tibiae were
significantly different from those of VectorTg mice at 2 and 8 months of age. Specifically,
HMWTg epiphyses displayed modifications of the trabecular architecture that are indicative of
early OA-like changes (Fig. 1C & D). At 2 months of age the bone volume/tissue volume
(BV/TV) of the HMWTg epiphysis was decreased in both the femur and tibia by 35% (P <0.01)
and 11% (P <0.01), respectively, compared to the VectorTg. The trabecular thickness (Tb.Th) of
the HMWTg epiphysis was decreased in the femur and tibia at 2 months by 16% (P <0.001) and
11% (P <0.01), respectively, compared to the VectorTg. Also, at 2 months the femur of HMWTg
mice had an increase in trabecular spacing (Tb.Sp) by 16% (P <0.05) and a decrease in
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trabecular number (Tb.N) by 17% (P <0.05) compared to VectorTg. Moreover, at 8 months of
age, the epiphysis of the femur and tibia of HMWTg had a decrease in BV/TV by 42% (P <0.05)
and 27% (P <0.05), respectively, compared to the VectorTg. The Tb.Sp was increased by 32%
(P <0.05) and the Tb.N was decreased by 25% (P <0.05) in 8-month-old HMWTg femoral
epiphyses, compared those of the VectorTg.

2.4.2. Histological changes in VectorTg and HMWTg cartilage
Articular cartilage integrity was determined histologically using Safranin-O staining to examine
proteoglycan content in 2, 8, and 18-month-old mice. A dramatic decrease in Safranin–O
staining (proteoglycan content) and articular cartilage thickness was found in HMWTg knees at
all ages, particularly on the lateral side (Fig. 2A, circled area). Osteophytes, formed through
endochondral ossification of cartilaginous tissue, were also present in 18-month-old HMWTg
knees (Fig. 2B). The average tibial articular cartilage thickness was significantly decreased in 2month-old HMWTg knees compared to VectorTg by 56%, in 8-month-old HMWTg compared to
VectorTg by 65%, and in 18 month HMWTg compared to VectorTg by 62%(Fig. 2C).
We also examined GFP localization in the joints of 1-month-old HMWTg and VectorTg
mice as a readout of transgene expression. GFP was expressed by osteocytes and osteoblasts in
the bone areas of both strains, but was absent from the articular cartilage and tendons. Notably,
GFP was markedly more intense in HMWTg tissues. These results confirmed bone-targeted
overexpression of HMW FGF2 isoforms in the HMWTg mice (Fig. 3).
Furthermore, in order to confirm that overexpression of the LMW FGF2 isoform does not
lead to joint degeneration, we examined knees of 19-month-old VectorTg and LMWTg mice and
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found that there was no phenotypic difference in the subchondral bone by x-ray imaging and
similar articular cartilage thickness between both groups (Fig. 4).

2.4.3. Expression of OA markers in VectorTg and HMWTg knees
Total RNA was extracted from knee joints of 2-month-old VectorTg and HMWTg mice and used
for measurement of mRNA of genes that are typically upregulated in OA articular cartilage,
including MMP-13 (a collagenase) and type X collagen (hypertrophic chondrocyte marker). Both
MMP-13 and type X collagen mRNA expression was significantly increased in HMWTg joints
(Fig. 5A). Additionally, immunohistochemistry was utilized to determine the localization and
expression of MMP-13 and ADAMTS-5 (the major aggrecan degrading enzyme in murine
cartilage). In 2-month-old HMWTg joints, expression of MMP-13 and ADAMTS-5 was
increased in all joint tissues but particularly in the articular cartilage, compared to VectorTg (Fig.
5B & C). MMP-13 expression was also present in the enlarged tendon area of HMWTg knees,
but was not present in VectorTg. MMP-13 expression in 8-month-old HMWTg joints was
observed within the articular cartilage and in a developing osteophyte area (Fig. 5B) and
ADAMTS-5 expression in the articular cartilage was also increased compared the VectorTg (Fig.
5C). In 18-month-old HMWTg knees, MMP-13 expression was increased overall compared to
the VectorTg, most notably in the enlarged tendon areas near the femur (Fig. 5B). Similarly,
ADAMTS-5 expression was increased in these HMWTg knees compared to the VectorTg knees,
particularly along the articular cartilage (Fig. 5C). Furthermore, RNAscope was utilized to
examine Col X expression, which showed an increase in labeled articular chondrocytes in
HMWTg knees compared to the very few cells which were labeled in the VectorTg at 2 months
of age (Fig. 5D).
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Since HMWTg mice developed an OA phenotype and since multiple cytokines, growth
factors and oxidative stress and their downstream signaling pathways have been involved in the
regulation of OA like changes in the subchondral bone as well as hypertrophic-like changes in
osteoarthritic articular chondrocytes (65, 66), we examined gene expression in whole joints from
2-month-old Vector and HMWTg mice. We observed significant increases in the mRNA for
bone morphogenetic protein 2 (Bmp2), bone morphogenetic protein 4 (Bmp4), insulin like
growth factor 1(Igf1), interleukin 1 beta (Il-1β), and hypoxia inducible factor 1(Hif1α) compared
to the VectorTg (Table 3). There was no increase in transforming growth factor beta (Tgfβ1 or
Tgfβ3) or tumor necrosis factor alpha (Tnfα) or Indian hedgehog (Ihh), (data not shown). We
also observed a significant increase in the transcription factors, Sex determining region Y box 9
(Sox9), and nuclear factor kappa B subunit 1 (Nf-κb1) (Fig. 6A) in joints from HMWTg
compared with Vector. Since Sox9 and NF-κB signaling is important in the response to multiple
inducers of OA, we also examined P65 subunit of NF-κB by immunohistochemistry and found
there was expression throughout the articular cartilage of 2-month-old HMWTg mice, but no
expression in the VectorTg (Fig. 6B). Also, Sox9 expression was dramatically increased in the
cartilage and menisci of HMWTg joints compared to VectorTg (Fig. 6C).

2.4.4. Evaluation of characteristics of osteoarthopathies in VectorTg and HMWTg joints
Although vascular endothelial growth factor (Vegf) mRNA levels were similar in both genotypes
(data not shown), there was increased VEGF protein expression in 2-month-old HMWTg
subchondral bone and articular cartilage (a typically avascular region) compared to VectorTg
joints (Fig. 7A). Alkaline phosphatase staining was used to visualize the expression and
localization of hypertrophic chondrocytes, which showed an increase in HMWTg joints,
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encroaching upon a greater area of the articular surface compared to that of the VectorTg (Fig.
7B). Mineral deposition was determined by von Kossa staining (Fig. 7C). VectorTg mice showed
mineralization, which corresponded to the alkaline phosphatase stained area of the articular
cartilage, whereas, the HMWTg mice showed less mineral deposition in areas that did contain
alkaline phosphatase-positive chondrocytes. Also, there was evidence of mineralization on the
meniscus in HMWTg mice (Fig. 7B & C).

2.4.5. Expression of FGF Receptors and ligands in VectorTg and HMWTg knee joints
Since HMWTg mice overexpress the HMW FGF2 isoforms, which results in increased FGF2 in
bone (38) and also increased FGF23 expression in serum and bone (38), we examined total FGF2
and FGF23 expression within the joint. Fgf2 mRNA expression was significantly increased in 2month-old HMWTg compared to the VectorTg (P <0 .01) and Fgf23 mRNA expression was
increased but did not reach significance (Fig. 8A). Immunohistochemistry confirmed that FGF2
protein expression was increased in the articular cartilage, meniscus, and tendons in HMWTg
mice compared to VectorTg at 2 and 8 months of age (Fig. 8B). Similarly, FGF23 protein
expression was markedly increased within the articular cartilage and subchondral bone of
HMWTg mice, notably in the developing osteophyte at 8 months (Fig. 8C).
FGF2 and FGF23 signal through the receptors FGFR1 and FGFR3, which have also been
implicated in OA disease. FGFR1 and FGFR3 mRNA expression was significantly increased in
whole joints of 2-month-old HMWTg compared to the VectorTg mice (Fig. 9A & B).
Immunostaining revealed that FGFR1 protein was localized in the articular cartilage and
meniscus of the joints, and appeared to be increased in HMWTg knees, compared to those of
VectorTg at 2 months of age and even more strikingly at 8 months of age compared to the
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VectorTg control (Fig. 9C). Immunohistochemistry also showed that HMWTg and VectorTg
knees had similar expression of FGFR3 protein, particularly within the articular cartilage, which
was decreased at 8 months of age compared to 2 months for both genotypes (Fig. 9D).

2.5 Discussion
Although there have been numerous studies describing FGF2 and its involvement in OA,
we provide evidence, for the first time, that the HMW isoforms of FGF2 may be a key
component that contributes to joint degeneration in mice. In this study we demonstrated that
mice overexpressing the nuclear HMW FGF2 isoforms in bone spontaneously exhibit signs of
osteoarthropathy as early as 2 months of age and continue to develop a phenotype that mimic the
progression of OA in human XLH subjects (40, 41). This phenotype included skeletal
abnormalities of the knee, such as thinning of subchondral bone followed by sclerosis and
osteophyte formation, modifications in trabecular architecture, such as increased trabecular space
and decreased trabecular number, thinning of the articular cartilage, upregulated expression of
cartilage degrading enzymes, and defective mineralization within the joint. Moreover, key FGF
family members including FGF2, FGF23, and FGFR1 were overexpressed throughout the knee
joint tissue of HMWTg mice.
Conflicting studies have been published about the role of FGF2 in joint homeostasis and
degeneration (17,18,21,24). This study, in which we show that bone targeted overexpression of
FGF2 HMW isoforms is accompanied by joint degeneration in transgenic mice, is consistent
with catabolic potential of FGF2 in OA (17,18,21,24), which we suggest is probably due to the
HMW FGF2 isoforms. HMWTg mice displayed an increase in total FGF2 in articular cartilage,
yet the overexpression of the HMW FGF2 isoforms is in osteoblastic lineage cells. This increase
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in FGF2 within the cartilage may be driven by the overexpression of the HMW FGF2 isoform in
the subchondral bone due to the crosstalk of the bone-cartilage unit. Previous reports suggest that
products of OA subchondral bone can be secreted into the joint space and accessed by the
articular cartilage via synovial fluid (66), and there is evidence to suggest that the HMW FGF2
isoform can be released from the cell (67). Also, since the Hyp mouse has been found to develop
degenerative osteoarthropathy (44) and we reported that these mice have an increase in the
HMW FGF2 isoforms in osteocytes, (38) as do our HMWTg mice, this suggests that these HMW
FGF2 isoforms are contributing to the OA-like phenotype in the Hyp mouse. We posit that the
changes within the Hyp mouse joint are due in part to the HMW FGF2 isoforms and not the
LMW FGF2 isoforms, as the knees from our LMWTg mice appeared to be nearly identical to
those of the VectorTg control furthermore we reported that the LMWFGF2 isoform was not
overexpressed in bones of the Hyp mouse (38).
HMWTg mice develop many similar characteristics of osteoarthropathy to those
displayed by Hyp mice. Both HMWTg mice and Hyp mice (44) display thinning of articular
cartilage without evidence of fraying, a hallmark of osteoarthropathy found in XLH subjects (40,
41). HMWTg and Hyp mice have overall hypomineralization (68, 69), which may be
contributing to the observed thin articular cartilage, as hypomineralization of the subchondral
bone, is believed to contribute to the expansion of the tibial plateau in response to increased load
in an OA knee, consequently causing articular cartilage to stretch (70), resulting in decreased
thickness. HMWTg joints had an increase in alkaline phosphatase and type X collagen staining,
particularly in the area of the deep zone, as well as, throughout the cartilage, suggesting there
could be an advancement of the tidemark and subchondral bone, a common OA-like
characteristic (71, 72). Although there was increased alkaline phosphatase staining throughout
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the articular cartilage in HMWTg mice, the von Kossa staining did not correspond to the alkaline
phosphatase-positive chondrocytes, which was similarly observed in Hyp mice (44), implying
that defective mineralization is occurring. Vascular invasion of articular cartilage usually
accompanies the advancement of the tidemark, which was evident in Hyp mice (44), as well as,
HMWTg mice, which displayed VEGF expression at the interface of the articular cartilage and
subchondral bone. Angiogenesis was present in the articular cartilage, a typically avascular
tissue, is another hallmark of joint degeneration and may contribute to endochondral osteophyte
formation in HMWTg and Hyp joints. Generally, HMWTg and Hyp mice share many of the
same phenotypic traits of osteoarthropathy that are common to humans with XLH.
Although there have been no studies investigating the subchondral bone trabecular
architecture in the Hyp mouse, there is increasing evidence that articular cartilage and
subchondral bone act together as a functional unit (66, 4). We reported modifications in
subchondral bone of HMWTg mice that are consistent with many osteoarthritic models (4, 3),
including thinning of bone in younger ages and sclerosis in older mice, which is prominent in
XLH subjects (41). Also, the BV/TV and trabecular number and thickness were decreased, while
the trabecular spacing was increased within the epiphysis of the femur and tibia. Other studies
have shown that these alterations of the subchondral bone lead to an imbalance in stress
distribution on the articular cartilage, ultimately leading to its degeneration (73). Thus, the
decrease in articular cartilage thickness that was observed in HMWTg mice could be due to the
modification of the underlying bone caused by the overexpression of the HMW FGF2 isoforms
in that area.
A differing characteristic between HMWTg and Hyp knee joints is the localization and
level of expression of articular cartilage matrix degradative enzymes, which are typically
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upregulated in degenerated joints. However, MMP13 is reduced in the joints of Hyp mice even
though they display signs of OA (44). In contrast, unlike Hyp mice, MMP13 expression was
significantly increased in the articular cartilage of our HMWTg mice at all ages, suggesting these
mice develop a more prototypical form of osteoarthropathy than Hyp mice (44). This elevation
of MMP-13 may be attributed to the increase in FGF2 expression we observed in HMWTg mice,
particularly in the articular cartilage, as it has been shown that FGF2 stimulates MMP-13
activation (17). HMWTg mice displayed increased ADAMTS5 protein expression within the
articular cartilage and areas of the joint compared to VectorTg at all ages. However, at 2 months
of age Adamts5 mRNA expression was not significantly increased between HMWTg and
VectorTg mice (data not shown). The lack of change in Adamts5 mRNA may be due to the age
at which the RNA was isolated (2 month old mice in our study). It should be noted that other
studies have reported that Adamts5 mRNA expression is not changed in early-stage human OA
cartilage but is significantly increased in late-stage degenerative joint disease (74).
The data from our study suggests that HMW FGF2 isoform overexpression in
osteoblastic lineage cells is contributing to the upregulation of cartilage degradative enzymes
within the joint. We therefore propose that the overexpression of the HMW FGF2 isoforms may
be contributing to osteoarthropathy in HMWTg mice by shifting catabolic over anabolic activity
in the joint, causing an imbalance in cartilage homeostasis.
FGFR1 is known to have an important role in OA in humans and mice (25,26,75). We
found that FGFR1 gene and protein expression were increased in HMWTg knees, which is
similar to other studies in which FGFR1 expression is increased in human osteoarthritic
chondrocytes (25). Our observation is also consistent with reported effects of inhibition of
FGFR1 signaling in murine articular cartilage, which attenuates OA progression (26). Since
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binding of FGF2 to FGFR1 leads to a cascade of events that are typically catabolic in articular
chondrocytes, including activation of NF-κB, which we determined was increased in HMWTg
joints, and MAPK pathways (76) it is possible that FGF2 overexpression in our model stimulates
matrix degradation and blocks natural anabolic functions, causing the premature and severe
osteoarthropathy we have observed. FGF2 also binds to FGFR3 with high affinity (25) and
activation of FGFR3 has been shown to have anabolic effects in articular cartilage (23, 27).
However, we found that similar patterns and levels of FGFR3 protein were present in the
articular cartilage of HMWTg and VectorTg mice. Similarly, other studies have shown that
FGFR3 expression is unchanged in mice that underwent surgical-induction of OA (77).
However, FGFR3 is decreased in human osteoarthritic chondrocytes in vitro (25). These studies
emphasize the inconsistent and potentially distinct roles of FGFR1 and FGFR3 in joint
homeostasis and degeneration. Since FGF2 binds both FGFR1 and FGFR3, which have
contrasting roles in cartilage homeostasis, the FGFR1/FGFR3 ratio is likely essential in the
biological outcome of FGF2. Although we found an increase in FGFR3 gene expression in
HMWTg joints, the ratio of FGFR1: FGFR3 gene expression was significantly greater than that
found in VectorTg (data not shown). This was also seen in human OA articular chondrocytes
compared to healthy chondrocytes (25). However, the increased FGFR3 gene expression
observed in this study could also reflect the inclusion of extracts used for this analysis. Indeed, it
has been found by microarray analysis that FGFR3 expression is significantly increased in the
subchondral bone of rats with degenerative joint disease (77). Additionally, FGFR3 gene
expression in our study may be increased due to an early repair response in HMWTg mice, as the
qPCR data is only for 2-month-old mice, and FGFR3 has been reported to promote anabolic
activities in articular cartilage (27). Future studies examining FGFR3 gene expression in older
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mice and in specific tissue types are needed to fully resolve the relationships between FGFR1,
FGFR3 and FGF2 in the joint.
HMWTg mice phenocopy most traits in XLH subjects, which includes increased FGF23
levels in serum and bone (38) and now similar osteoarthropathies (40, 41). Our lab has
previously shown that the HMW isoforms of FGF2 modulate and co-localize with FGF23 in
osteoblast and osteocytes in HMWTg mice (38). Thus, HMW FGF2 isoforms may be
contributing to OA through FGF23 signaling, as FGF23 expression is upregulated in human
osteoarthritic chondrocytes (45), which has been determined to drive MMP-13 expression (46),
and we also demonstrated that FGF23 protein and MMP-13 mRNA and protein expression was
increased within the joint, including the cartilage of HMWTg mice. Previous studies have shown
that the development of OA could be due to the activation of hypertrophic differentiation of
articular chondrocytes (78) and multiple signaling pathways are responsible including growth
factors, such as BMPS and IGF-1, cytokines such as IL-1β and transcription factors Hif, Nf-κB,
and Sox9 (65). Furthermore, although Sox9 is a marker for chondroprogenitor cells, studies have
shown there is an increase in Sox9 expression in human chondrocytes of early-stage OA (79), as
well as, murine osteoarthritic cartilage, particularly in areas of developing osteophytes (80).
Since we found a significant increase in the expression of genes of these pathways in HMWTg
joints, the OA-like phenotype may be caused by changes in the subchondral bone as well as
hypertrophic differentiation of chondrocytes due to modulation of these factors and signaling
molecules.
In conclusion, transgenic mice with bone-targeted overexpression of HMW FGF2
(HMWTg mice) developed OA-like characteristics that were not simply restricted to a single
component of the joint. Although changes in articular cartilage occurred, modifications within
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the subchondral bone were concurrently happening, likely due to the targeted overexpression of
the HMW FGF2 isoforms in bone in this model. Further studies will be necessary in order to
decipher the exact mechanism that causes this phenotype. Overall, HMWTg mice will serve as a
novel model for joint degeneration, particularly in the context of osteoarthropathy observed with
XLH, which could be used in future studies aimed at better understanding the pathophysiology
of osteoarthropathy and OA, and may offer new insight into how to treat this disabling disorder.
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2.6 Figures
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Figure 2.6.1. Radiographic and MicroCT analysis of subchondral bone in VectorTg and
HMWTg mice. A, Sagittal digital x-ray images of HMWTg knees show flattening of tibial
plateau (open arrow), thinning of subchondral bone (open arrowhead), osteophyte formation
(filled arrowhead), patellofemoral space narrowing (dashed arrow), and sclerotic bone (filled
arrow). N=4-11/group. B, High-resolution micro-computed tomography (μCT) images of
representative sagittal sections of all HMWTg samples show decreased trabecular bone in the
epiphyses, thinning of subchondral bone at 2 and 8 months of age (open arrowheads), flattening
of tibial plateau at 8 months of age (open arrow), and thickened sclerotic bone at 18 months of
age (filled arrowhead). Three-dimensional (3D) renderings reveal erosion and pitting of HMWTg
knees (arrows) while VectorTg knees maintain a smooth contour. C-D, 3D morphometric
parameters revealed a decrease in BV/TV, Tb.N, and Tb.Th and an increase in Tb.Sp in 2 and 8
month old HMWTg femoral and tibial epiphyses compared to VectorTg. BV/TV, trabecular
bone volume; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Th; trabecular
thickness. Values are the means ± SD. *P <0.05, **P <0.01, ***P<0.001, compared with
VectorTg. N=3/group.
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Figure 2.6.2. Proteoglycan content of VectorTg and HMWTg knees at 2, 8, and 18 months
of age. A, Safranin-O stained representative images showed a decrease in cartilage thickness in
all HMWTg samples. B, 18-month-old HMWTg knees showed severe cartilage loss and
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osteophyte development of mineralized cartilage (arrow) of femur. Bar = 200 μm. C, Mean
lateral tibial articular cartilage thickness of VectorTg and HMWTg. Values are the means ± SD,
n=3-4/group.
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Figure 2.6. 3. GFP expression in the frontal section of knees of 1-month-old VectorTg and
HMWTg mice. VectorTg mice created with the Col3.6-IRES/GFPsaph construct and HMWTg
mice created with the Col3.6-HMW Fgf2 isoforms-IRES-GFP construct reveal expression of any
GFP in the same location (area of bone), while GFP expression was overall increased in
HMWTg. The outlined white area is the corresponding box below, which is at a higher
magnification. This area of the lateral left side of the knee shows no GFP expression in articular
cartilage (dashed arrow) or tendon and meniscus regions. Nuclear stain (blue): To-Pro-3.
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Figure 2.6.4. VectorTg and LMWTg knees at 19 months of age are phenotypically similar.
A, Representative digital x-ray images show a comparable subchondral bone appearance in
VectorTg and LMWTg knees. N=4/group. B, Safranin-O stained representative images show a
similar cartilage phenotype and cartilage thickness in VectorTg and LMWTg samples. C, There
was no difference between the mean lateral tibial articular cartilage thickness of VectorTg and
LMWTg samples. Values are the means ± SD, n=3/group.
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Figure 2.6. 5. Matrix metalloproteinase 13 (MMP-13), a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS-5), and type X collagen (Col X) expression in
knees of VectorTg and HMWTg. A, Extraction of total RNA from knees of 2-month-old
VectorTg and HMWTg and quantification of Mmp-13, Adamts5 and ColX mRNA by real time
reverse transcription-PCR (qPCR). Values are the means ± SD. *P <0.05, n=7-8/group. B-C,
Representative immunohistochemical staining of VectorTg and HMWTg knees at 2, 8, and 18
months show increased protein expression of MMP-13 and ADAMTS-5 along articular cartilage
(arrows). MMP-13 expression was increased in the enlarged tendon area of HMWTg joints at 2
months of age (filled arrowhead) and in the developing osteophyte region of HMWTg joints at 8
months of age (red arrow). Increased MMP-13 expression at 18 months within area of tendon
was present in HMWTg (filled arrowheads) and absent in VectorTg (open arrowhead). D,
RNAscope shows increased Col X expression throughout the articular cartilage in HMWTg
(arrows) compared to VectorTg mice. Magnification = 20X. For IHC/RNAscope n=3-4/group.
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Figure 2.6. 6. NF-κB and Sox9 mRNA and protein expression in knees of 2-month-old
VectorTg and HMWTg. A, HMWTg knee joints have increased expression of NF-κB and Sox9
mRNAs. Values are the means ± SD. *P <0.05, ***P<0.001, n=7-8/group. B, Representative
immunohistochemical staining of HMWTg knees shows phospho-NF-κB p65 expression
throughout the articular cartilage (arrows), while no expression is present in VectorTg samples.
C, Representative images show increased expression of SOX9 along articular cartilage (arrows)
and meniscus of HMWTg joints, while there is relatively low expression in VectorTg joints.
Magnification= 10X; n=3/group.
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Figure 2.6.7.Comparison of VEGF, von Kossa, and alkaline phosphatase staining in 2month-old VectorTg and HMWTg knees. A, HMWTg knee joints show VEGF expression
(arrows) in the subchondral bone and at the interface of the articular cartilage and subchondral
bone. No cells were labeled for VEGF in VectorTg knee sections. B, Representative alkaline
phosphatase staining of knees from HMWTg shows more alkaline phosphatase-positive articular
chondrocytes (arrows) compared to VectorTg. C, Corresponding von Kossa stained sections
reveal a decrease in mineral deposition despite the presence of alkaline phosphatase-positive
chondrocytes in HMWTg knees, relative to VectorTg knees. Magnification= 10X; n=3/group.
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Figure 2.6.8. Fgf2 and Fgf23 mRNA and protein expression in knees of VectorTg and
HMWTg mice. A, Fgf2 and FGF23 mRNA levels were increased in 2-month-old HMWTg
knees compared with VectorTg. Values are the means ± SD. **P <0.01, n=7-8/group. B,
Representative immunohistochemical staining of FGF2 in 2 and 8 month old HMWTg articular
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cartilage is increased (arrows). C, FGF23 protein expression is increased in 2 and 8 month old
HMWTg articular cartilage (arrows) and bone (arrowheads). For IHC n=3-4/group; Bar = 50 μm.
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Figure 2.6.9. FGFR1 and FGFR3 expression in knees of HMWTg and VectorTg mice. A-B,
FGF2 and FGF23 mRNA level was significantly increased in HMWTg knees at 2 months of age.
Values are the means ± SD. *P ≤ 0.05, **P <0.01, n=7-8/group. C, Representative
immunohistochemical staining of FGFR1 was more robust in HMWTg cartilage at 2 and 8
months (arrows). D, Immunohistochemical staining of FGFR3 reveals similar protein expression
within articular cartilage of VectorTg and HMWTg at 2 and 8 months (open arrows). For IHC
n=3-4/group; Bar = 50 μm.
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Table 2.6.1. Antibody Table
Peptide/Protein
Target

Name of
Antibody

Manufacturer/
Catalog
Number
Abcam, ab39012

Species Raised
(Monoclonal/Polyclonal)

Dilution

MMP13

Anti-MMP13
antibody

Rabbit;polyclonal

1:100

ADAMTS5

AntiADAMTS5
antibody

Abcam, ab41037

Rabbit;polyclonal

1:100

FGF-2

FGF-2 (147)

Santa Cruz, sc79

Rabbit;polyclonal

1:50

FGFR-3

p-FGFR-3
(Tyr 724)

Santa Cruz, sc33041

Rabbit;polyclonal

1:100

VEGF

VEGF (A-20)

Rabbit;polyclonal

1:100

FGF-23

Anti-FGF-23
antibody

Santa Cruz, sc152
R & D Systems,
MAB26291

Rat;Monoclonal

1:100

FGFR-1

Flg (C-15)

Rabbit;polyclonal

1:50

NF-κB

Anti-NF-κB
p65
(phosphoS536)
antibody

Santa Cruz, sc121
Abcam,
ab131109

Rabbit;polyclonal

1:100

SOX9

SOX9
antibody

Abcam, ab59265

Rabbit;polyclonal

1:50
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Table 2.6.2. Primers used in qRT-PCR
Gene

Forward

Reverse

β-actin

5’-atggctggggtgttgaaggt-3’

5’-atctggcaccacaccttctacaa-3’

Mmp-13

5’-ctttggcttagaggtgactgg-3’

5’-aggcactccacatcttggttt-3’

Adamts5

5’-cctgcccacccaatggtaaa-3’

5’-ccacatagtagcctgtgccc-3’

Col10a1

5’-gggaccccaaggacctaaag-3’

5’-gcccaactagacctatctcacct-3’

Vegf

5’-gcacatagagagaatgagcttcc-3’

5’-ctccgctctgaacaaggct-3’

Fgf2

5’-gtcacggaaatactccagttggt-3’

5’-cccgttttggatccgagttt-3’

Fgf23

5’-acttgtcgcagaagcatc-3’

5’-gtgggcgaacagtgtagaa-3’

FGFR1

5’-gactgctggagttaatacca-3’

5’-ctggtctctcttccagggct-3’

FGFR3

5’-gttctctctttgtagactgc-3’

5’-agtacctggcagcacca-3’

Sox9

5’-agtacccgcatctgcacaac-3’

5’-acgaagggtctcttctcgct-3’

Nf-kb1

5’-gaaattcctgatccagacaaaaac-3’

5’-atcacttcaatggcctctgtgtag-3’

Bmp-2

5’-agcgtcaagccaaacacaaacag-3’

5’-ggttagtggagttcaggtggtcag-3’

Bmp-4

5’-gccggagggccaagcgtagccctaag-3’

Igf-1

5’-gtgagccaaagacacaccca-3’

5’-ctgcctgatctcagcggcacccacatc
-3’
5’-acctctgattttccgagttgc-3’

IL-1β

5’-gcaactgttcctgaactcaact-3’

5’-atcttttggggtccgtcaact-3’

Hif1α

5’-caagatctcggcgaagcaa-3’

5’-ggtgagcctcataacagaagcttt-3’
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Table 2.6.3. Gene expression in knee joints of VectorTg versus HMWTg mice
Gene

VectorTg

HMWTg

p-value

Bmp-2

0.95 ± 0.28

1.56 ± 0.59

0.003

Bmp-4

1.35 ± 0.50

2.68 ± 1.53

0.008

Igf-1

1.52 ± 0.64

2.59 ± 1.62

0.041

IL-1β

1.16 ± 0.41

2.08 ± 1.06

0.005

Hif1α

1.29 ± 0.47

2.52 ± 1.54

0.008
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Chapter 3

Ablation of low-molecular-weight fibroblast growth factor 2 (FGF2) accelerates murine
osteoarthritis while loss of high-molecular-weight FGF2 offers protection
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3.1 Abstract
FGF2 is an essential growth factor implicated in osteoarthritis (OA), and deletion of fulllength FGF2 leads to murine OA. However, the FGF2 gene encodes both high-molecular-weight
(HMW) and low-molecular-weight (LMW) isoforms, and the effects of selectively ablating
individual isoforms, as opposed to total FGF2, has not been investigated in the context of OA.
We undertook this study to examine whether mice lacking HMW FGF2 (Fgf2HMWKO) or LMW
FGF2 (Fgf2LMWKO) develop OA and to further characterize the observed OA phenotype in
Fgf2ALLKO mice. Fgf2HMWKO mice never developed OA, but 6- and 9-month-old Fgf2LMWKO and
Fgf2ALLKO mice displayed signs of OA, including eroded articular cartilage, altered subchondral
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bone and trabecular architecture, and increased OA marker enzyme levels. Even with mechanical
induction of OA, Fgf2HMWKO mice were protected against OA, while Fgf2LMWKO and Fgf2ALLKO
displayed OA-like changes of the subchondral bone. Before exhibiting OA symptoms,
Fgf2LMWKO or Fgf2ALLKO joints displayed differential expression of genes encoding key regulatory
proteins, including IL-1β, insulin-like growth factor 1, bone morphogenetic protein 4, hypoxiainducible factor 1, B-cell lymphoma 2, Bcl2- associated X protein, a disintegrin and
metalloproteinase with thrombospondin motifs 5, ETS domain–containing protein, and sexdetermining region Y box 9. Moreover, Fgf2LMWKO OA cartilage exhibited increased FGF2,
FGF23, and FGFR1 expression, while Fgf2HMWKO cartilage had increased levels of FGFR3,
which promotes anabolism in cartilage. These results demonstrate that loss of LMW FGF2
results in catabolic activity in joint cartilage, whereas absence of HMW FGF2 with only the
presence of LMW FGF2 offers protection from OA.

3.2 Introduction
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of
chronic disability worldwide, characterized by overall joint degeneration, primarily of the knee
(1). Specific hallmarks of OA include articular cartilage degeneration (82), osteophyte formation
(3), and dynamic modification of trabecular architecture of the underlying bone characterized by
thinning subchondral bone in early stages of OA disease due to an increase in bone resorption
with subsequent sclerosis of bone in later stages (4). In the articular cartilage, excessive catabolic
activity results in matrix degradation via upregulation of metalloprotease enzymes, including
matrix metalloproteinase 13 (MMP-13) and a disintegrin and metalloproteinase with
thrombospondin motifs 5 (ADAMTS-5) (8,9,82). The pathogenic mechanisms that underlie these
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morphological phenotypes remain largely unknown. There is an urgent need for additional
studies in order to identify therapeutic targets to prevent and treat OA disease, as there are
currently no effective treatment options beyond total joint replacement (17).
Recently, the involvement of members of the fibroblast growth factor (FGF) family,
particularly FGF2, has received considerable attention in the regulation of cartilage and joint
homeostasis (18,21). There is conflicting evidence which demonstrates both catabolic and
anabolic potential of FGF2 in the joint. Specifically, exogenous FGF2 simulates MMP-13 and
ADAMTS-5 production in articular cartilage explants in vitro (18,24) and the level of FGF2 in
OA synovial fluid is nearly twice that of healthy knees (21), suggesting catabolic functions.
Conversely, Fgf2 knockout (Fgf2ALLKO) mice develop spontaneous and surgically-induced OA
more frequently and severely than their wild type (WT) littermates (24), suggesting an anabolic
role for FGF2 in the joint. Additional studies are clearly necessary to further define the role that
FGF2 plays in joint homeostasis and potentially in OA etiology.
Importantly, the FGF2 gene encodes multiple protein isoforms including the high
molecular weight (HMW) isoforms and the low molecular weight (LMW) isoform. The LMW
isoform is translated from the traditional AUG start codon, while the HMW isoforms are
initiated upstream of the LMW start site from individual CUG codons (29). In humans there are
three HMW FGF2 isoforms (22, 22.5, 24kDa), and in rodents there are two HMW FGF2
isoforms (21, 22kDa). The HMW FGF2 isoforms contain a nuclear localization sequence and
remain in the nucleus to function as an intracrine factor (36). In humans and rodents there is one
LMW FGF2 isoform, which is transported out of the cell to function as an autocrine/paracrine
growth factor (37). Although deletion of full-length FGF2 leads to OA, the implications of
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separately ablating the individual isoforms in joint homeostasis and potentially in OA
pathogenesis has not been addressed.
In this study we investigated if selectively deleting the HMW or LMW isoforms would
affect the OA phenotype. Mice with a deficiency of HMW FGF2, Fgf2HMWKO mice, were
previously generated and characterized (36) and of importance had increased bone mineral
density (BMD) compared to WT mice (37). In a similar manner mice lacking LMW FGF2,
Fgf2LMWKO mice, were generated and previously characterized (33) and found to have decreased
BMD compared to WT mice (34). We have recently shown that mice that overexpress the
HMW FGF2 isoforms develop degenerative joint disease (83), so we hypothesized that
Fgf2LMWKO mice (which only express the high molecular weight FGF2 isoform), but not
Fgf2HMWKO mice, would develop OA. The aim of our study was to examine Fgf2HMWKO and
Fgf2LMWKO mice for any evidence of spontaneous and mechanically-induced OA, while
confirming and further characterizing the OA phenotype in Fgf2ALLKO mice. The results of this
novel study are of particular importance given the contrasting data of the involvement of FGF2
in OA, and for the first time show the differing effects of the distinct isoforms in the
development of the disease.
3.3 Materials and Methods

3.3.1 Animals
Fgf2ALLKO mice were previously developed on a Black Swiss 129Sv background (19) and
genotyping was performed using primers as previously described (84,35). Fgf2HMWKO mice were
formerly generated on a at the GEMM Core at the University of Arizona by gene-targeted
introduction of polymorphisms, using a Tag and Exchange strategy, to remove the alternative
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CUG codon start sites required to translate the HMW isoforms of FGF2 (14) and genotyping was
performed using primers previously described (36). Fgf2LMWKO mice were generated in a similar
manner to remove the ATG translational start site (33), and genotyping was performed using
primers previously described (33). All mice were developed on a Black Swiss 129Sv background
and deletion of the gene or selective isoform is constitutive. Heterozygote mice for each
genotype were bred and housed in the transgenic facility in the Center for Comparative Medicine
at UConn Health and all experiments were performed with littermate controls. Unless otherwise
indicated, all data presented involved male mice. The UConn Health Institute of Animal Care
and Use Committee approved all animal procedures.

3.3.2 Radiological analyses and Micro-computed tomography
Digital x-ray images of murine knee joints taken in the sagittal and frontal planes were
obtained with a SYSTEM MX 20 from Faxitron X-ray Corporation (Faxitron X-ray Corp.,
Wheeling, IL) and taken under constant conditions (26 kV at 6-s exposure). Imaging of knee
architecture was performed using ex vivo micro-computed tomography (μCT40, ScanCo Medical
AG, Bassersdorf, Switzerland).

3.3.3 Histologic Assessment
Mice were sacrificed utilizing the approved CO2 method for euthanasia and whole knee
joints were removed, fixed in 4% paraformaldehyde for 6 days, and decalcified with 14% EDTA
solution at 4°C. Samples were processed for paraffin embedding in a frontal orientation and 7μm alternate sections were obtained. Following de-paraffinization and rehydration of the
sections, Safranin-O staining of glycosaminoglycans was performed using 0.1% aqueous
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Safranin-O and counterstained with Weigert’s Iron Hematoxylin and 0.02% aqueous Fast Green.
Additional tissue sections were stained with hematoxylin and eosin (H&E). All histological
images were captured using Nikon TS100 microscope interfaced with SPOT software. Using
Safranin-O stained sections, the severity of cartilage destruction was assessed histologically by a
single observer blinded with regard to the mouse group using the recommended scoring system
from Glasson et al. (85) (0= normal; 0.5= loss of proteoglycan without structural changes, 1=
small fibrillation without cartilage loss, 2= vertical clefts down to layer directly beneath
superficial layer/some loss of surface lamina, 3= vertical clefts/erosion down to calcified
cartilage layer which extends <25% of articular surface, 4= vertical clefts/erosion down to
calcified cartilage layer which extends 25-50% of articular surface, 5= vertical clefts/erosion
down to calcified cartilage layer which extends 50-75% of articular surface, 6= vertical
clefts/erosion down to calcified cartilage layer which extends >75% of articular surface).
Scoring was performed on all articular surfaces within each section using 4 separate
representative sections from each knee, closest to the center of the joint, from 5 different samples
from each genotype. The mean score of the medial tibial plateau (n=5/group) or mean overall
(n=4-5/group) score was reported.
Histomorphometric measurements were made in the same blinded, nonbiased manner,
using the OsteoMeasure image analysis system (R & M Biometrics, Nashville, TN) equipped
with a Nikon E400 microscope (Nikon Inc., Melville, NY). The region of subchondral trabecular
bone of the epiphysis in the femur and tibia, was previously established (86), and analyzed for
the following histomorphometric parameters: bone volume/tissue volume (BV/TV), trabecular
thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular number (Tb.N), using 3
representative samples closest to the center of the joint from each different genotype.
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3.3.4. Immunohistochemistry
Immunohistochemical staining was performed on 7-μm paraffin embedded sections using
the ImmunoCruz™ ABC Staining System (Santa Cruz Biotechnology, CA, USA). After sections
were de-paraffinized and rehydrated, slides underwent antigen retrieval by incubation at 95°C
with 10mM sodium citrate buffer for 10 minutes and then cooled to room temperature for 30
minutes. Endogenous peroxidase activity was then blocked by incubating sections with 3%
hydrogen peroxide in water for 15 minutes. Following blocking sections with 10% serum for one
hour at room temperature, the slides were incubated with primary antibodies in blocking buffer
overnight at 4°C. A negative control slide was used each time, which was instead incubated with
blocking serum overnight. The following primary antibodies were used: rabbit anti-MMP13,
1:100 (Abcam, ab39012), rabbit anti-ADAMTS5, 1:100 (Abcam, ab41037), rabbit anti-FGF2,
1:50 (Santa Cruz, sc-79), anti-FGF-23, 1:100 (R & D Systems, MN, USA, MAB26291), rabbit
anti-FGFR-1 (Flg C-15)1:50 (Santa Cruz, sc-121), rabbit anti-pFGFR-1, 1:50 (Abnova,
PAB0471), rabbit anti-pFGFR-3 (Tyr 724), 1:100 (Santa Cruz, sc-33041), and rabbit antiphosphop44/42 MAPK (Cell Signaling, 4376S). After washing with TBS containing 0.1%
Tween 20, the appropriate 1:200 biotinylated secondary antibody was applied at room
temperature for 30 minutes. Finally, slides were washed and developed with DAB Peroxidase
Substrate kit (Vector Laboratories, Burlingame, CA, USA), and counterstained with Harris
hematoxylin.
3.3.5. Mechanical Induction of OA
Under isoflurane-induced anesthesia, mice were subjected to a single session of external
compressive loading of the right tibiae, while left legs served as contralateral controls. The
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electromagnetic loading machine (ElectroForce 3100; Bose Co., Eden Prairie, MN, USA)
applied a peak load level of 9.5N at a frequency of 4Hz for 1,200 cycles (5 min) and mice were
sacrificed 2 weeks after mechanical compression and intact knees were fixed in 4%
paraformaldehyde. This mechanical loading protocol was previously demonstrated to induce
OA-like cartilage and bone alterations 2 weeks after loading (16).

3.3.6. RNA isolation and real time PCR
Total RNA was isolated from whole knee joints, to include all structures of the joint
above the growth plate, following skin and bulk muscle removal from 2 month old male mice
from all genotypes, in a method previously described (24). Following snap-freezing by liquid
nitrogen, TRIzol reagent (Invitrogen) was used to extract RNA from the tissue. For real-time
quantitative RT-PCR (qRT-PCR) analysis, RNA was reverse-transcribed to cDNA using RNA to
cDNA EcoDry Premix kit (Clontech Inc., A Takara Bio Company). A Bio-Rad MyiQTM
instrument (BIO-RAD Laboratories Inc. Hercules, CA) using iTaqTM Universal SYBR Green
Supermix (Bio-Rad, CA, USA) was utilized for qPCR. The relative change in mRNA level was
normalized to the mRNA level of beta-actin (β-actin), a housekeeping gene, which served as an
internal reference for each sample. Table 1 lists the primers, synthesized by IDT (Integrated
DNA Technologies, Inc., CA), for the genes of interest. N=6-8/group.

3.3.7. Statistical analysis
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Data is presented as mean ± standard deviation (SD). Student’s t-test was used to analyze
differences between groups and considered significant at p values less than 0.05, unless
otherwise stated.

3.4 Results

3.4.1. Radiographic phenotype of joints of male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type
littermates
Digital radiographic examination revealed no abnormalities of the subchondral bone of
the knee in all 2 months old samples of Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and WT littermate
controls (Fig. 1). At 6 months of age all (10 of 10) Fgf2ALLKO and (9 of 9) Fgf2LMWKO knee joints
displayed evidence of joint destruction, flattening of tibia, and osteophyte formation on the
posterior tibial plateau compared to the WT controls. These OA-like alterations were also
evident in 9 months old Fgf2ALLKO (4 of 4) and Fgf2LMWKO (8 of 8), while Fgf2HMWKO knees were
phenotypically similar to WT at all ages and showed no radiographic indications of OA (Fig. 1).
X-rays of knees in female mice displayed the same result as males of all genotypes (data not
shown), indicating that gender does not influence the OA phenotype in these mice.

3.4.2. Histological phenotype of knees of male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type
littermates
Articular cartilage integrity was determined histologically by Safranin-O staining in 2, 6, and 9
months old Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and WT littermate controls. At 2 months of age
there was no difference in proteoglycan content, cartilage thickness, or Safranin-O intensity
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between Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and WT knees. By 6 and 9 months of age, both
Fgf2ALLKO and Fgf2LMWKO joints showed spontaneous fibrillation of cartilage (arrowheads), areas
of complete cartilage loss (arrows), and evidence of osteophyte formation (Fig. 2A). Safranin-O
stained Fgf2HMWKO cartilage appeared to have similar cartilage integrity to the WT at all ages
(Fig. 2A). The severity of cartilage destruction and extent of chondral damage was graded in 6
months old samples from at least 20 Safranin-O sections from the joint, per group (see
Experiment Procedures) and the average score of the medial tibial plateau was reported. The
score of Fgf2ALLKO was significantly higher than WT, p=.002 and Fgf2LMWKO was significantly
higher than the WT littermate, p=.004. The histologic score showed no significant difference
between Fgf2HMWKO and WT, p=.126 (Fig. 2B). Also, H & E-stained 6 month old Fgf2LMWKO
joints showed inflammation in the medial tendon and synovium and enlarged meniscus, which
was not present in WT littermates or Fgf2HMWKO and WT littermates (Fig. 2C). Fgf2ALLKO H & Estained sections showed cartilage loss, but less evidence of inflammation (Suppl. Fig. 1A).

3.4.3. Micro-computed tomography and histomorphometric analyses of male Fgf2HMWKO,
Fgf2LMWKO, and wild-type littermate knees
Reconstructed 3D images of 6 months old Fgf2LMWKO joints display bony outgrowths
(closed arrowheads), indentations, and wearing away of the tibial surface (open arrowhead),
while the Fgf2HMWKO renderings show a smooth and flat shape of the subchondral surface which
was consistent with both types of WT littermates (Fig. 3A). MicroCT-scanned 2D images show
tibial osteophyte formation and thinning of subchondral femoral bone (dashed arrow) of
Fgf2LMWKO compared to the WT (arrow). The Fgf2LMWKO images also display alterations in the
trabecular architecture in the femoral and tibial epiphyses, particularly evident in the sagittal
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view, which includes loss of trabeculae and increased spacing between trabeculae. These OA
characteristics were not observed in the Fgf2HMWKO or WT littermates (Fig. 3A).
Histomorphometry revealed there was no significant difference between bone volume/tissue
volume (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular
number (Tb.N) in both of the epiphyses of the femur and tibia between Fgf2HMWKO or WT
littermates (Fig. 3B). However, the BV/TV of the femoral epiphyses was 50% less (p< .001) in
the Fgf2LMWKO compared to the WT and 47% less (p< .001) in the tibia. Tb.Th was significantly
lower in Fgf2LMWKO compared to the WT in the femur (p=.014) and tibia (p=.004). The Tb.Sp of
the Fgf2LMWKO epiphysis was significantly increased in the femur and tibia by 96% (p< .001) and
61% (p< .001) respectively, compared to that of the WT. Also, there was a 39% reduction (p<
.001) in Tb.N. of the femoral epiphysis and a 33% reduction (p=.001) in the tibia of the
Fgf2LMWKO compared to the WT (Fig.3C). The findings were similarly significant in 6 month old
Fgf2ALLKO epiphyses (Suppl. Fig. 1B). By histomorphometry, at 2 months of age the BV/TV,
Tb.Th, Tb.Sp, and Tb.N of the epiphysis of both the femur and tibia was not significantly
different between all genotypes and the littermate WT controls (Suppl. Fig. 2).

3.4.4. Expression of OA markers in male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type
littermates
Immunohistochemistry was used to examine the presence of OA marker protein
expression within the joint tissues. At 6 months of age, MMP-13 (a collagenase) was greatly
enhanced within the articular cartilage of the Fgf2ALLKO and Fgf2LMWKO compared to the WT,
whereas, Fgf2HMWKO cartilage had comparable MMP-13 staining to that of the WT littermate
(Fig. 4A). ADAMTS-5 (the major aggrecan degrading enzyme in murine cartilage) was also
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increased throughout the tissues of the joints of 6-month-old Fgf2ALLKO and Fgf2LMWKO,
particularly in the enlarged medial meniscus and tendon area and developing osteophyte region
of Fgf2LMWKO. Examining the same area of the Fgf2HMWKO knee, immunohistochemistry revealed
similar or slightly less ADAMTS-5 expression compared to WT (Fig. 4B).

3.4.5. Examination of age induced OA in female Fgf2HMWKO, and mechanically-induced OA in
male Fgf2HMWKO, Fgf2LMWKO, and wild-type littermates
In order to determine if Fgf2HMWKO mice are protected from age-related OA, we examined
knees of 2-year-old female Fgf2HMWKO mice (n=6). The x-ray images of WT joints appeared to
have some evidence of sclerotic bone formation, while the Fgf2HMWKO joints did not (Fig.5A).
Safranin-O staining showed a loss of proteoglycan content, a decreased superficial zone layer,
and slight fraying of cartilage in WT sections, while this was not observed in Fgf2HMWKO
cartilage. The total joint OA score was significantly increased in WT compared to Fgf2HMWKO ,
p=.020 (Fig. 5A-B). Immunohistochemical staining of the OA marker, ADAMTS-5, showed
little expression in tibial articular chondrocytes of Fgf2HMWKO mice compared to the many
labeled chondrocytes of the WT (Fig. 5C). It would be expected that mice aged to 2 years would
display signs of OA.
To further verify that Fgf2HMWKO mice are protected from OA, we induced joint damage
in 21 month old Fgf2HMWKO and WT mice by subjecting the right leg to a single session of cyclic
tibial loading, previously shown to induce OA-changes in 2 weeks after loading (86). The 3D
and 2D microCT images of Fgf2HMWKO right knees showed no indications of OA in the
subchondral bone and had a similar phenotype to that of the left contralateral control and the
right and left legs of the WT (Fig. 5D). In order to determine if challenging Fgf2LMWKO knees will
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accelerate the OA phenotype, right legs of approximately 12 week old Fgf2LMWKO mice
underwent the same tibial loading procedure. Two weeks after loading, 3D microCT images of
the right leg show an uneven tibial surface and evidence of erosion compared to the smooth
surface observed in the left contralateral control and in both knees of the WT littermates. The
sagittal view shows thinning of subchondral bone, loss of trabeculae and increased trabecular
spacing in the epiphyses compared to the left control (Fig. 5E). To confirm the validity of the
mechanically-induced OA model the same protocol was carried out on Fgf2ALLKO knees, which
have previously shown to have accelerated OA following surgical induction (24), and 2 weeks
after loading the microCT images revealed similar OA-like changes in the right leg that were
observed in Fgf2LMWKO mice (Suppl. Fig. 1C).
Histologically, 21 months old WT joints that underwent tibial loading showed signs of
cartilage damage, whereas, the contralateral controls and Fgf2HMWKO joints (both loaded and nonloaded) did not exhibit evidence of OA, and is reflected in the scores of the medial tibial plateau
(Fig. 5F). Safranin-O staining of right loaded knees of 12 weeks old Fgf2LMWKO mice revealed
fibrillation of tibial cartilage and decreased size of the superficial zone. The histologic score of
loaded Fgf2LMWKO knees was significantly higher than the controls (Fig. 5G).

3.4.6. Expression of OA-like genes in male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type
littermates
Total RNA was isolated from knee joints of 2 month old Fgf2ALLKO, Fgf2HMWKO,
Fgf2LMWKO, and their WT littermates and used for measuring mRNA levels of genes that have
been implicated in OA, including cytokines, growth factors, and components involved in OA-
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like changes in subchondral bone or hypertrophy of chondrocytes. qPCR analysis showed
significant increases in the mRNA from both Fgf2ALLKOand Fgf2LMWKO knees for interleukin 1
beta (Il-1β), insulin like growth factor 1(Igf1), bone morphogenetic protein 4 (Bmp4), hypoxia
inducible factor 1(Hif1α), and the ratio of B-cell lymphoma 2 (Bcl2) and Bcl2-Associated X,
apoptosis regulator (Bax), while Fgf2 was significantly increased in Fgf2LMWKO knees and
decreased in Fgf2ALLKO knees (Fig. 6A). We also observed significant increases in the mRNA
from only Fgf2ALLKO knees for Adamts5, ETS domain-containing protein-1 (Elk-1), Sex
determining region Y box 9 (Sox9), and FGFR1 (Fig. 6B). qPCR showed increases in the mRNA
from only Fgf2LMWKO knees for vascular endothelial growth factor (Vegf), type X collagen
(ColX), FGFR3, and Fgf23 (Fig. 6C). The expression of Fgf23 was too low to be detected in
Fgf2ALLKO joints and mRNA expression of any gene of interest was not significantly modulated in
Fgf2HMWKO joints compared to WT.

3.4.7. Expression of FGF ligands and receptors in knees of male Fgf2ALLKO, Fgf2HMWKO,
Fgf2LMWKO, and wild-type littermates
Immunohistochemistry confirmed that Fgf2ALLKO joints did not have FGF2 expression, as
shown by the absence of any labeled cells in the articular cartilage compared to the WT
littermate at 2 and 6 months of age (Fig. 7A&B). Fgf2HMWKO cartilage had similar FGF2
expression to the WT at 2 months of age (Fig.7A), but appeared to have decreased FGF2
expression by 6 months of age (Fig. 7B). However, Fgf2LMWKO articular cartilage showed
enhanced FGF2 expression at 2 and 6 months of age (Fig.7A&B) compared to the WT littermate.
Localization of the protein confirmed that FGF2 was detected in the cytoplasm and the nuclei of
chondrocytes in Fgf2HMWKO joints, similarly to the WT, whereas FGF2 was only detected in the
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nuclei of Fgf2LMWKO chondrocytes and not present in Fgf2ALLKO tissue (Fig. 7C). Immunostaining
revealed increased FGF23 protein expression in Fgf2LMWKO articular cartilage at 2 months of age
compared to WT, while cartilage of Fgf2ALLKOand Fgf2HMWKO had similar FGF23 expression to
that of the WT (Fig. 8A). By 6 months of age immunostaining displayed enhanced FGF23
expression in Fgf2ALLKO along the articular surface compared to WT and Fgf2LMWKO maintained
high FGF23 expression compared to WT. Fgf2HMWKO cartilage still had similar FGF23
expression to the WT littermate (Fig. 8B). FGF2 and FGF23 signal through FGFR1 and FGFR3,
which are known to be involved in OA etiology. At 6 months of age, articular chondrocytes had
increased total FGFR1 expression in Fgf2ALLKO knees and Fgf2LMWKO joint tissues had increased
total FGFR1 expression, notably in developing osteophyte regions and the inflamed tendon areas
compared to the WT. Fgf2HMWKO joints had similar total FGFR1 expression to that observed in
WT (Fig. 9A). Phosphorylated FGFR1 expression was present in Fgf2ALLKO cartilage and
appreciably expressed in Fgf2LMWKO chondrocytes (Fig. 9B). Conversely, at 6 months of age
Fgf2ALLKO and Fgf2LMWKO knees had a marked decrease in phosphorylated FGFR3 expression as
observed in articular cartilage in the femur (Fig. 9C). Also, phospho-FGFR3 protein expression
was enhanced in knees of 6 months old Fgf2HMWKO compared to WT cartilage (Fig. 9C).
Expression of phospho-ERK1/2, a downstream component of FGF2/FGF23/FGFR signaling,
was only present in Fgf2LMWKO cartilage (Fig. 9D).

3.5 Discussion
Though there have been several publications reporting the contribution of FGF2 in the
progression of OA, including a previous study which showed that deletion of full-length FGF2 in
mice leads to enhanced OA (24), we describe for the first time that the varying FGF2 isoforms
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have differing roles in degenerative joint disease. In this study we demonstrated that mice
lacking only the LMW FGF2 isoform (Fgf2LMWKO) develop signs of spontaneous and
mechanically-induced OA, including cartilage destruction, inflammation, modifications of the
subchondral bone, and upregulation of degradative enzymes. Fgf2HMWKO mice appeared to be
protected from OA, as they did not display these characteristics, despite age or mechanical
induction. Moreover, Fgf2ALLKO and Fgf2LMWKO knees already had enhanced expression of genes
involved in multiple signaling pathways known to promote OA at just 2 months of age, which
preceded the OA phenotype. Also, essential FGF family members including FGF23 and FGFR1
were upregulated in Fgf2ALLKO and Fgf2LMWKO joints, while FGFR3 was increased in Fgf2HMWKO
cartilage.
Despite there being numerous contradictory findings about the involvement of FGF2 in
cartilage homeostasis and degradation (18,21,24), this study supports the idea that FGF2 can
have both an anabolic and catabolic effect dependent upon the presence or absence of the
isoform. Fgf2LMWKO mice displayed classic hallmarks of OA that began at 6 months of age,
which persisted to 9 months of age and were not restricted to simply one component of the joint.
Histological examination revealed frayed cartilage, areas of complete cartilage loss, and
evidence of endochondral ossification of developing osteophytes, which was most apparent on
the medial side. As indicated by the OA score, these destructive alterations of cartilage were not
present in joints of Fgf2HMWKO mice. Following mechanical induction the 21 months old WT
littermates of Fgf2HMWKO mice displayed histologic evidence of OA, as their age would make
them more susceptible when challenged, whereas, the Fgf2HMWKO mice appeared protected. Also,
articular cartilage of Fgf2LMWKO and Fgf2ALLKO mice had increased expression of degradative
enzymes, MMP-13 and ADAMTS-5, while Fgf2HMWKO joints did not. Additionally, subchondral
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bone was thinner, contained osteophytes, had a decrease in trabecular number and thickness and
an increase in trabecular spacing in only Fgf2LMWKO and Fgf2ALLKO mice, indicating that this
particular OA phenotype encompasses all joint tissues.
In order to determine if there are modifications of gene expression of pathways involved
in OA induction before the disease phenotype occurs in Fgf2LMWKO and Fgf2ALLKO mice, RNA
was isolated from whole knee joints at 2 months of age. It has been found that progression of OA
may be caused by activation of hypertrophic differentiation of articular chondrocytes (78) and
various signaling pathways are implicated which include cytokines such as Il-1β, growth factors
such as IGF-1 and BMP4, and transcription factor Hif1α (65). Since joints from both Fgf2LMWKO
and Fgf2ALLKO mice were found to have significant increased expression in genes of those
pathways, it suggests that in addition to the observed modifications of the underlying bone, that
hypertrophic differentiation of articular chondrocytes is driving the OA phenotype. Typically,
the Bcl2/Bax ratio is decreased in mRNA taken from OA cartilage, as the Bcl2 protein protects
chondrocytes from cell death, while Bax accelerates apoptosis (87). However, it was found that
Bcl2 expression declines with age, while Bax expression remains constant, suggesting that the
shift of this ratio to favor apoptosis would only occur in cartilage with age (88). Thus, the young
age in which we examined the Bcl2/Bax ratio in Fgf2LMWKO and Fgf2ALLKO knees may be why we
did not observe a decrease.
Although Fgf2ALLKO and Fgf2LMWKO shared a similar OA phenotype and modulation of
related genes, there were some differences that were observed, indicating that joint degeneration
might not be caused by the equivalent mechanism, as the Fgf2LMWKO mice still possess the HMW
FGF2 isoforms. Through H & E staining we observed inflammation of the tendon and synovium
in Fgf2LMWKO knees, whereas this particular aspect was absent in Fgf2ALLKO knees, which was
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consistent with the previous study that examined OA in Fgf2ALLKO mice and reported no evidence
of synovitis (24). Also, the qPCR analysis showed some distinct differences in gene expression
of mRNA taken from 2 month old joints of Fgf2ALLKO and Fgf2LMWKO mice. Fgf2ALLKO joints
already had significant increases in the catabolic enzyme Adamts5 and the transcription factor,
Elk-1, which induces MMP-13 expression (89) and Sox9, which although is a chondroprogenitor
marker, has been shown to be increased in human chondrocytes with early-stage OA (79).
Fgf2LMWKO mRNA did not have this early high expression of these genes, but instead had
increased Vegf and ColX expression, signifying chondrocyte hypertrophy, another hallmark of
OA cartilage.
As mentioned earlier there are numerous conflicting studies on the role that FGF2 plays
in OA and this is mainly due in part to its binding affinity for FGFR1 and FGFR3, which have
contrasting roles in cartilage homeostasis. While FGFR1 is increased in human OA
chondrocytes, drives cartilage destruction (25), and its inhibition attenuates OA in murine
cartilage (26), FGFR3 is decreased in human OA chondrocytes (25), promotes anabolic activity
in cartilage (27), and its absence accelerates murine OA (28). Regardless of the essential absence
of mRNA and protein expression of FGF2 in Fgf2ALLKO joints, there was a significant increase in
FGFR1 mRNA at 2 months of age and protein expression at 6 months of age. This early increase
of FGFR1 expression could be due to enhanced expression of other FGF ligands, as many other
than FGF2, bind to FGFR1, including FGF1 which has been shown stimulate catabolic effects in
chondrocytes and was increased in OA tissues of rat and humans (90,91). Once the Fgf2ALLKO
mice displayed signs of OA, the cartilage had increased expression of FGF23, which can bind to
FGFR1 and is known to drive MMP13 expression in osteoarthritic chondrocytes (46). Also, the
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expression of activated FGFR1 was not as great as the expression of total FGFR1, implying that
the OA phenotype may be attributed to modulation of a different pathway.
Interestingly, Fgf2LMWKO had increased FGF2 mRNA and protein expression at 2 months
and increased protein expression still at 6 months of age, and while FGFR3 expression was
enhanced at 2 months of age, phospho-FGFR3 was not detected at 6 months, yet total and
phospho-FGFR1 expression was greatly increased. This initial increase in FGFR3 may be an
early repair response, as the RNA was taken at only 2 months of age and signaling through
FGFR3 can promote anabolic activities in cartilage (27). Furthermore, FGF23 expression was
increased at 2 and 6 months of age in Fgf2LMWKO joints, which can also signal through FGFR1 to
push the OA phenotype via regulation of the MEK/ERK cascade (46) and we observed enhanced
phospho-ERK expression in only Fgf2LMWKO only. Intriguingly, Fgf2LMWKO knees showed
upregulation of the same genes as mice that overexpressed the HMW FGF2 isoforms, including
FGF23, which also developed degenerative joint disease (83), suggesting that lack of LMW
FGF2 may be causing a compensatory effect, which would increase HMW FGF2, which is
driving the OA phenotype and would explain the significant increase in FGF2 protein and
mRNA. Mice that overexpress the LMW FGF2 isoform do not develop OA (83) and Fgf2HMWKO
mice were protected from OA despite age and mechanical induction and had an increase in
FGFR3 expression at 6 months of age. Similarly, this suggests that it is the HMW FGF2 isoform
responsible for the OA phenotype and that the presence (or possible overcompensation) of LMW
FGF2 confers a chondroprotective effect.
We demonstrated that chondrocytes of Fgf2LMWKO expressed FGF2 solely and robustly in
the nucleus, confirming that Fgf2LMWKO mice only express HMW FGF2 since this isoform
remains in the nucleus (36). Fgf2HMWKO mice expressed FGF2 in the nucleus and cytoplasm,

65

having similar expression to WT. This data is consistent with previous investigators who showed
that HMW FGF2 has nuclear localization and LMW FGF2 is expressed in cytoplasm and
nucleus (29) and others who demonstrated that cardiomyocytes from Fgf2LMWKO and Fgf2HMWKO
mice have varying localization of FGF2 via immunohistochemistry (92) (as there are no
commercially available antibodies to detect the isoforms). Notably, this study highlights the
importance of the possible roles that each FGF2 variant may have in cartilage homeostasis, as the
relative expression levels of the FGF2 isoforms in both adult human and murine healthy or OA
cartilage is unknown. Though in fetal growth plate cartilage it was determined that LMW FGF2
was only expressed in resting cartilage, whereas HMW FGF2 was expressed by proliferating
chondrocytes (93). This evidence further supports the idea that HMW FGF2 is the isoform
contributing to OA, since during OA the normally quiescent chondrocytes begin to proliferate,
recapitulating a process that resembles chondrocyte differentiation during endochondral
ossification (94).
Finally, our observations provide insight into the varying roles of FGF2 and its isoforms
in OA and why global deletion of FGF2 leads to the disease. Though the exact molecular basis of
the involvement of FGF2 isoforms still requires further investigation, this data offers a more
thorough understanding of the potential future treatment or management of OA.
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3.6 Figures

Figure 3.6.1. Time course of radiographs of male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and
wild-type littermates at 2, 6, and 9 months of age. Sagittal digital x-ray images of all
genotypes appeared to have the same subchondral bone phenotype at 2 months old. Osteophyte
formation (arrows) was visible in the posterior tibial plateau of Fgf2ALLKO and Fgf2LMWKO knees at
6 and 9 months old. N=4-10/age group/genotype.
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Figure 3.6.2. Analysis of cartilage integrity of male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and
wild-type littermates. A, Safranin-O stained representative images of medial area of knees show
similar histological appearances between all genotypes and their wild-type controls at 2 months
of age. At 6 and 9 months of age Fgf2ALLKO and Fgf2LMWKO joints display fibrillation of articular
cartilage (open arrowheads) and complete loss of cartilage (arrows) n=4-6/group. B, Mean
medial tibial plateau OA score of Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and WT at 6 months of
age. Values are means ± SD, *p <0.05, **P <0.01, n=5/group. C, H & E stained representative
images of 6 month old Fgf2LMWKO displays inflammation of the tendon and synovium (circle).
N=3/group. Magnification=10X.
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Figure 3.6.3. MicroCT imaging and histomorphometric analysis of subchondral bone of
male Fgf2HMWKO, Fgf2LMWKO, and wild-type littermates at 6 months old. A, Threedimensional (3D) renderings reveal pitting and erosion (open arrowhead) and osteophyte
formation (closed arrowhead) of Fgf2LMWKO knees, while Fgf2HMWKO and all WT knees maintain
a smooth contour. High-resolution micro-computed tomography (μCT) 2D images of
representative sections of all Fgf2LMWKO samples show osteophyte formation of tibia (closed
arrowhead) and thinning of femoral subchondral bone (dashed arrow) compared to the thicker
femoral subchondral bone (arrow) of the WT littermate. Fgf2LMWKO epiphyses display decreased
trabecular thickness and number and increased trabecular spacing compared to WT and
Fgf2HMWKO epiphyses. N=3-7/group. B, Histomorphometric parameters of Fgf2HMWKO and WT
femoral and tibial epiphyses are similar. C, Histomorphometric parameters of Fgf2LMWKO femoral
and tibial epiphyses reveal decreases in BV/TV, Tb.Th, and Tb.N and an increase in Tb.Sp
compared to WT. BV/TV, trabecular bone volume; Tb.Th, trabecular thickness Tb.Sp, trabecular
separation; Tb.N, trabecular number. Values are the means ± SD. *P <0.05, **P <0.01, ***P
<0.001 N=5/group.
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Figure 3.6.4. Matrix metalloproteinase 13 (MMP-13), a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS-5) expression in knees of 6 month old male
Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type littermates. A, Representative
immunohistochemical staining shows increased protein expression of MMP-13 along tibial
articular cartilage of Fgf2ALLKO and Fgf2LMWKO (arrows) compared to WT littermates, while
Fgf2HMWKO and WT have similar MMP-13 expression. B, Representative images show increased
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expression of ADAMTS-5 in the enlarged tendon and meniscus area of the medial tibia in both
Fgf2ALLKO and Fgf2LMWKO (dashed arrows) compared to WT littermates, whereas Fgf2HMWKO and
WT have similar ADAMTS-5 expression of the same area. Magnification=10X, n=3/group.
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Figure 3.6.5. Fgf2HMWKO are protected from spontaneous (females) and mechanicallyinduced (males) OA. A, 2 year old Fgf2HMWKO and WT have similar subchondral bone
phenotypes as determined by x-ray. Safranin-O staining of lateral side of joint shows loss of
proteoglycan content (closed arrowhead) and fibrillation of cartilage (open arrowhead),
compared to the more robust proteoglycan content of Fgf2HMWKO samples. N=4-6/group. B, Mean
total joint OA score of Fgf2HMWKO is significantly lower than WT. Values are means ± SD, n=45/group. C, Representative immunohistochemical staining shows decreased protein expression of
ADAMTS-5 along tibial articular cartilage of Fgf2HMWKO (dashed arrow) compared to
expression in WT littermates (arrows). D-E, 3D reconstructed images and μCT images of sagittal
sections of right tibial-loaded knees (2 weeks after loading) of 21 month old Fgf2HMWKO mice
appear to have a similar appearance to the left contralateral control and both left and right knees
of WT. Right tibial loaded knees of Fgf2LMWKO mice show erosion of the tibial surface (arrow)
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compared to the left contralateral control and all samples in D. Sagittal images display decreased
femoral subchondral bone (dashed arrow) and increased trabecular spacing and decreased
trabecular number in epiphyses compared to the contralateral control n=3-4/group. F, Safranin-O
staining shows fissures (arrow) in cartilage of right tibial-loaded knees (2 weeks after loading) of
21 months old WT littermates of Fgf2HMWKO mice. OA score of right medial tibia of WT
littermates of Fgf2HMWKO mice was significantly higher than all others. G, Right tibial loaded
knees of 12 week old Fgf2LMWKO mice (2 weeks after loading) show fraying (arrow) and a
significantly higher OA score than controls. Values are means ± SD, p <0.05**p <0.01, ***p
<0.001.
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Figure 3.6.6. Gene expression of joints of 2 month old male Fgf2ALLKO, Fgf2HMWKO,
Fgf2LMWKO, and wild-type littermates. A, qPCR analysis of genes with modulated expression in
both Fgf2ALLKO and Fgf2LMWKO samples. B, qPCR analysis of genes with increased expression
only Fgf2ALLKO samples. C, qPCR analysis of genes with increased expression in only Fgf2LMWKO
samples. Values are the means ± SD. *P <0.05**P <0.01, ***P <0.001, n=6-8/group.
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Figure 3.6.7. FGF2 protein expression in 2 and 6 month old male Fgf2ALLKO, Fgf2HMWKO,
Fgf2LMWKO, and wild-type littermates. A, Immunohistochemical staining of tibial articular
cartilage shows no FGF2 expression in 2 month old Fgf2ALLKO tissue (dashed arrows) compared
to WT. Fgf2LMWKO cartilage had increased FGF2 expression (arrow) compared to WT. B, 6
month old femoral articular cartilage shows no FGF2 expression in Fgf2ALLKO cartilage (dashed
arrow) compared to WT. FGF2 expression was increased in Fgf2LMWKO cartilage (arrow)
compared to WT cartilage. Magnification=10X. C, Higher magnification of 6 months old joints
shows localization of FGF2 isoforms. In WT and Fgf2HMWKO cartilage, FGF2 is expressed in
both the nucleus and cytoplasm of chondrocytes. FGF2 is only expressed in the nuclei Fgf2LMWKO
cartilage. No FGF2 expression was detected in Fgf2ALLKO tissue. Magnification =40X,
n=3/group.
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Figure 3.6.8. FGF23 protein expression in 2 and 6 months old male Fgf2ALLKO, Fgf2HMWKO,
Fgf2LMWKO, and wild-type littermates. A, Representative immunohistochemical staining shows
enhanced protein expression of FGF23 in tibial articular cartilage of Fgf2LMWKO (arrows)
compared to WT littermates, while Fgf2ALLKO and Fgf2HMWKO had similar FGF23 expression to
their WT littermates at 2 months of age. B, Both Fgf2LMWKO and Fgf2ALLKO had increased FGF23
staining in articular cartilage compared to WT, and Fgf2HMWKO had similar FGF23 expression to
their WT at 6 months of age. Magnification=10X, n=3/group.
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Figure 3.6.9. FGFR1, FGFR3, and ERK protein expression in 6 months old male Fgf2ALLKO,
Fgf2HMWKO, Fgf2LMWKO, and wild-type littermates. A, Immunohistochemical staining shows
total FGFR1 expression was more robust in tibial articular cartilage of Fgf2ALLKO (arrows).
FGFR1 was also increased in the joints of Fgf2LMWKO, particularly in the enlarged meniscus and
developing osteophytes areas (arrows). Fgf2HMWKO had similar FGFR1 expression to the WT. B,
phospho-FGFR1 was present in tibial cartilage of Fgf2ALLKO (arrow). Fgf2LMWKO cartilage had
increased phopho-FGFR1 expression (arrows). C, phospho-FGFR3 expression was decreased in
Fgf2ALLKO and Fgf2LMWKO femoral articular cartilage (dashed arrows) compared to WT, while
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Fgf2HMWKO had increased FGFR3 staining (arrow). D, phospho-ERK expression was only
detected in Fgf2LMWKO cartilage (arrows). Magnification=10X, n=3/group.
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Table 3.6.1. Primers used in qRT-PCR.
Gene

Forward

Reverse

Actb

5’-atggctggggtgttgaaggt-3’

5’-atctggcaccacaccttctacaa-3’

Elk1

5’-ttggaggcctgtctggaggctgaa-3’

5’-agctcttccgatttcaggtttggg-3’

Adamts5

5’-cctgcccacccaatggtaaa-3’

5’-ccacatagtagcctgtgccc-3’

Col10a1

5’-gggaccccaaggacctaaag-3’

5’-gcccaactagacctatctcacct-3’

Vegf

5’-gcacatagagagaatgagcttcc-3’

5’-ctccgctctgaacaaggct-3’

Fgf2

5’-gtcacggaaatactccagttggt-3’

5’-cccgttttggatccgagttt-3’

Fgf23

5’-acttgtcgcagaagcatc-3’

5’-gtgggcgaacagtgtagaa-3’

Fgfr1

5’-gactgctggagttaatacca-3’

5’-ctggtctctcttccagggct-3’

Fgfr3

5’-gttctctctttgtagactgc-3’

5’-agtacctggcagcacca-3’

Sox9

5’-agtacccgcatctgcacaac-3’

5’-acgaagggtctcttctcgct-3’

Bmp4

5’-gccggagggccaagcgtagccctaag-3’

5’-ctgcctgatctcagcggcacccacatc-3’

Igf1

5’-gtgagccaaagacacaccca-3’

5’-acctctgattttccgagttgc-3’

Il1b

5’-gcaactgttcctgaactcaact-3’

5’-atcttttggggtccgtcaact-3’

Hif1a

5’-caagatctcggcgaagcaa-3’

5’-ggtgagcctcataacagaagcttt-3’

Bcl2

5’-gagagcgtcaacagggagatg-3’

5’-ccagcctccgttatcctgga-3’

Bax

5’-tgaagacaggggcctttttg-3’

5’-aattcgccggagacactcg-3’
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Supplemental Figure 3.6.1. Fgf2ALLKO male develop spontaneous and mechanically-induced
OA. A, H & E stained representative images of 6 months old Fgf2ALLKO samples show loss of
articular cartilage and no inflammation. N=3/group. B, Histomorphometric parameters of
Fgf2ALL KO femoral and tibial epiphyses reveal decreases in BV/TV, Tb.Th, and Tb.N and an
increase in Tb.Sp compared to WT. Values are the means ± SD. *P <0.05, **P <0.01, ***P
<0.001, N=5/group. C, Right tibial loaded knees of Fgf2ALL KO mice have pitting of the tibial
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surface (arrow) compared to the left contralateral control and WT. Sagittal images display
decreased femoral subchondral bone (dashed arrow) and increased trabecular spacing and
decreased trabecular number in femoral epiphyses compared to the contralateral control and WT.
N=4-5/group.
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Supplemental Figure 3.6.2. Histomorphometric analysis of subchondral bone of 2 months
old male Fgf2ALLKO, Fgf2HMWKO, Fgf2LMWKO, and wild-type littermates. A-C,
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Histomorphometric parameters of femoral and tibial epiphyses are similar between Fgf2ALLKO
Fgf2HMWKO, Fgf2LMWKO, and their respective WT littermates. Values are the means ± SD,
n=3/group.
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FGF23 regulates Wnt/β-catenin signaling-mediated osteoarthritis in mice overexpressing
high molecular weight FGF2
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4.1 Abstract
Although humans with X-linked hypophosphatemia (XLH) and the Hyp mouse, a murine
homologue of XLH, are known to develop severe degenerative joint disease, the exact
mechanism which drives the osteoarthritic (OA) phenotype remains unclear. Mice that
overexpress the high molecular weight FGF2 isoforms (HMWTg mice) phenocopy both XLH
and Hyp, including OA with increased fibroblast growth factor 23 (FGF23) production in bone
and serum. Since HMWTg cartilage also has increased FGF23 expression and there is crosstalk
between FGF23-Wnt/β-catenin signaling, the purpose of this study was to determine if OA
observed in HMWTg mice is due to FGF23 mediated-canonical Wnt signaling in chondrocytes
given that both pathways are implicated in OA pathogenesis. HMWTg OA joints had decreased
Dkk1, Sost, and Lrp6 expression with increased Wnt5a, Wnt7b, Lrp5, Axin2, phospho-GSK3,
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Lef1, and nuclear β-catenin as indicated by immunohistochemistry or qPCR analysis.
Chondrocytes isolated from HMWTg mice had enhanced alcian blue and alkaline phosphatase
staining and increased FGF23, Adamts5, Il-1β, Wnt7b, Wnt16, and Wisp1 gene expression and
phospho-GSK3 protein expression as indicated by Western blot compared to chondrocytes of
Vector control and chondrocytes harvested from mice overexpressing the low molecular weight
isoform, which were shown to be protected from OA. Canonical Wnt-inhibitor treatment rescued
some of those parameters in HMWTg chondrocytes, seemingly delaying the initial accelerated
chondrogenic differentiation. Neutralizing FGF23Ab treatment was able to partly ameliorate OA
abnormalities of the subchondral bone and reduce expression of degradative/hypertrophic
chondrogenic markers in HMWTg mouse joints in vivo. These results demonstrate that
osteoarthropathy of HMWTg is at least partially due to FGF23 modulated Wnt/β-catenin
signaling in chondrocytes.

4.2 Introduction
Osteoarthritis (OA) is a chronic disabling joint disease, mainly of the knee, which affects
millions of people and disturbs all areas of the joint, including the subchondral bone, meniscus,
and synovium, but is primarily characterized by the degradation of articular cartilage (1,6). This
cartilage is comprised of unique chondrocytes which synthesize extracellular matrix (ECM)
components and a variety of catabolic and anabolic factors in order to maintain healthy cartilage
homeostasis. When this balance is perturbed and various biochemical pathways are activated
within chondrocytes, there is a breakdown of the ECM by degradative enzymes, inflammation
occurs, and chondrocytes undergo dedifferentiation and hypertrophy, ultimately leading to OA
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(6,7). Unfortunately, the molecular mechanisms that cause OA are not fully understood and there
is a crucial need to further study these biochemical pathways that contribute to the disease in
order to identify therapeutic targets to effectively treat OA.
The Wnt signaling pathway has been a well-recognized regulator in not only skeletal and
embryonic development, but in cartilage homeostasis and the pathophysiology of OA (48,49).
Though there have been contradictory findings regarding either the activation or inhibition of
Wnt signaling on joint homeostasis (51,52), there are numerous studies that suggest that cartilage
degradation is a result of excessive canonical Wnt signaling, which is initiated by binding to lowdensity lipoprotein receptor (LRP) 5 or 6, leading to stabilization and nuclear translocation of βcatenin, and transcription of its target genes, such as Wnt-induced signaling protein-1 (WISP1),
which has been shown to be increased OA cartilage of mice (52-56). Specifically, Wnt7b, an
exclusively canonical ligand, was found to be upregulated in human OA cartilage (55) and
Wnt16 and nuclear -catenin expression were increased in OA cartilage with a decreased
expression of Wnt inhibitors (54,56). Also, human and mouse OA cartilage was found to have an
upregulation of LRP5, and mice lacking Lrp5 were protected from experimental OA (53). Thus,
aberrant canonical Wnt/-catenin signaling negatively impacts cartilage.
Interestingly, fibroblast growth factor 23 (FGF23) is upregulated in human OA
chondrocytes (45) and exogenous expression of FGF23 stimulates hypertrophy and increases
FGFR1 production in chondrocytes (46,47). FGF signaling has been found to augment nuclear catenin levels by inactivating glycogen synthase kinase (GSK) 3 (60), and Wnt/-catenin
activity was shown to stimulate FGF23 promoter activity in osteoblasts (61). Together these
studies imply that FGF23 and canonical Wnt signaling cooperatively may be contributing to OA.
We previously published that mice which overexpress the high molecular weight isoforms of
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FGF2 (HMWTg mice) in osteoblastic lineage cells spontaneously develop signs of OA as early
as 2 months of age, including increased degradative enzymes, a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS) and matrix metalloproteinases (MMPs), FGF23, and
FGFR1 expression in the cartilage, while mice that overexpress the low molecular weight
isoform (LMWTg) were protected from OA (83). HMWTg mice mimic subjects that have Xlinked hypophosphatemia (XLH) in that they have decreased bone mineral density, rickets,
osteomalacia, hypophosphatemia, osteoarthropathy, and elevated levels of FGF23, which are
traits in which the HMWTg mice phenocopy Hyp mice (38), a murine homologue of XLH.
Additionally, Wnt signaling components are enhanced in Hyp mice (61, 62). The aim of this
study is determine if the OA phenotype observed in HMWTg mice is due to increased FGF23
and canonical Wnt signaling in chondrocytes.

4.3 Materials and Methods

4.3.1. Experimental animals
All animal protocols were approved by the UConn Health Institute of Animal Care and Use
Committee. We have previously described in detail the generation of HMWTg and Vector
(control) transgenic mice (38). HMWTg mice overexpress human HMW FGF2 isoforms in bone,
using the Col3.6-HMW-IRES-green fluorescent protein-sapphire (GFPsaph) construct in which a
CAT fragment of the previously generated construct, Col3.6-CAT-IRS-GFPsaph, was replaced
with HMW isoforms of human FGF2 cDNA. Thus, allowing HMW and GFPsaph to be
concurrently overexpressed from a single bicistronic mRNA. Vector mice overexpress the
transgene cassette, Col3.6-IRES/GFPsaph, without the additional FGF2 coding sequences.
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Col3.6-CAT-IRES-GFPsaph or Col3.6-IRES/GFPsaph construct inserts were released via
digestion by AseI and AflII. Microinjections in the pronuclei of fertilized oocytes were
performed at the Gene Targeting & Transgenic Facility at UCONN Health. To establish the
individual transgenic mouse lines founder mice of the F2 (FVBN) strain were mated with wildtype mice. Mice that overexpress the human LMW isoform FGF2 were generated using a similar
method as described above (34). In vivo studies used male homozygous Vector and HMWTg
without antibody treatment and female homozygous Vector and HMWTg mice for antibody
treatment studies. Both male and female 5 day old pups of Vector, HMWTg, and LMWTg were
used for all in vitro studies.

4.3.2. Histology
Following dissection 2-month-old murine knees were fixed in 4% paraformaldehyde, decalcified
using a 14% EDTA solution, processed for paraffin embedding in a frontal orientation, and cut
into 7-μm alternate sections. The ImmunoCruz ABC Staining System (Santa Cruz
Biotechnology) was used for all immunohistochemical staining. After sections were
deparaffinized and rehydrated, antigen retrieval was done by incubating sections with 10mM
sodium citrate buffer for 10 minutes at 95°C. To reduce endogenous target, slides were blocked
with 3% hydrogen peroxide in water for 15 minutes, then blocked for 1 hour with 10% serum,
and incubated with primary antibodies in blocking buffer at 4°C overnight. The following
primary antibodies were used (details can be found in Table 1): goat anti-SOST (R & D
Systems), rabbit anti-pLRP6(Bioss), rabbit anti-pLRP5 (Abcam), goat anti-WNT5A (R & D
Systems), rabbit anti-WNT7B (GeneTex), rabbit anti-pGSK3β (Abcam), rabbit anti-LEF1
(Sigma-Adlrich), rabbit anti-non-phospho β-catenin (Cell Signaling) rabbit anti-MMP13 (abcam),
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and goat anti-MMP19 (Santa Cruz). A negative control slide was used each time, which was

incubated overnight with only blocking serum. Sections were then washed and incubated with
the appropriate 1:200 biotinylated secondary antibody for 30 minutes. Finally, slides were
washed, developed with DAB Peroxidase Substrate kit (Vector Laboratories), and counterstained
with Harris hematoxylin.

4.3.3. RNA isolation and real time PCR
For in vivo studies, following removal of skin and bulk muscle of the knee, total RNA was
extracted from the entire joint which included all components above the growth plate using
TRIzol reagent (Invitrogen) (34). For real-time quantitative RT-PCR (qRT-PCR) analysis, the
RNA to cDNA EcoDry Premix kit (Clontech Inc., A Takara Bio Company) was used to reversetranscribe the RNA to cDNA . iTaqTM Universal SYBR Green Supermix (Bio-Rad, CA, USA)
and a Bio-Rad MyiQTM instrument (BIO-RAD Laboratories Inc. Hercules, CA) were utilized for
qPCR. The relative change in mRNA level was normalized to the mRNA level of Beta-actin (βactin), which served as an internal reference for each sample. For in vitro studies, RNA was
extracted from culture plates using TRIzol reagent and qPCR performed as described above.
Additionally, mRNA was normalized to the β-actin mRNA level and expressed as the foldchange relative to the appropriate Vector group. Table 2 lists the primers, synthesized by IDT
(Integrated DNA Technologies, Inc., CA), for the genes of interest.

4.3.4. Radiology and microcomputed tomography analysis
Digital x-rays of excised knee joints taken in the frontal plane were captured under consistent
conditions (26 kV at 6-s exposure) using a SYSTEM MX 20 from Faxitron X-ray Corporation
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(Faxitron X-ray Corp.). Imaging of knee architecture was performed using ex vivo microcomputed tomography (μCT40, ScanCo Medical AG, Bassersdorf, Switzerland). The following
morphometric parameters of the region of subchondral trabecular bone of the epiphysis in the
femur and tibia were analyzed by 3-dimensional (3D) microcomputed tomography (μCT): bone
volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and
trabecular number (Tb.N).

4.3.5. FGF23 neutralizing antibody treatment
Female HMWTg mice were treated with a rat anti-rat FGF23 neutralizing antibody (FGF23Ab)
(Amgen Inc.), at a dose of 10mg/kg body weight or control IgG (rat-anti-NGFPb-3F8-raIgG2a)
by intraperitoneal injection (ip) twice a week, beginning at 8 weeks of age for 6 weeks. This
dosage was previously established in our lab in a pilot experiment. Initially, Vector mice were
treated with control IgG (Vehicle) only, but an additional experiment that included Vector mice
treated with FGF23Ab (as an added control group) or control IgG treatment was performed by
initiating injections twice a week at 3 weeks of age for 6 weeks and combined into the study.
Mice were euthanized by CO2 and knees were collected. Sections were obtained by methods
described and Safranin-O staining using 0.1% aqueous Safranin-O with 0.02% aqueous Fast
Green and Weigert’s Iron Hematoxylin counterstain was performed.

4.3.6. Chondrocyte culture
Chondrocytes were dissected from approximately 5 day old male and female Vector, HMWTg,
and LMWTg pups from the femoral head, femoral condyles, and tibial plateau using a dissecting
Zeiss microscope. Cartilage was collected in high-glucose DMEM (Life Technologies) and
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digested in .25% trypsin (Life Technologies) for 30 minutes and then incubated with 500 U/ml of
collagenase type II (Worthington Biochemical Corporation) for 3 hours at 37°C. Cells were
collected and cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin
(P/S) (Life Technologies) (95) .The cells were plated at a density of 100,000 cells/cm2, incubated
for 7 days with media changes every other day, fixed, and stained with Alcian Blue (3% in acetic
acid, pH 2.5) (Poly Scientific) or Vector Blue Alkaline Phosphatase Substrate (Vector
Laboratories). For inhibitor experiments, chondrocyte culture medium was supplemented with
10µM IWR-1 endo (Santa Cruz) or .1% dimethyl sulfoxide (DMSO) on day 5 when cells are
approximately 70% confluent for 48 hours.

4.3.7. Western blot analysis
Protein was extracted from primary articular chondrocytes on day 7 in culture using 1×
radioimmune precipitation buffer (Cell Signaling Technology, Inc.), and protein concentration
was assayed with BCA protein assay reagent (Thermo Scientific). Following SDSpolyacrylamide gel electrophoresis on mini protean gels (Bio-Rad Laboratories), proteins were
transferred to Immuno-Blot PVD membranes (Bio-Rad Laboratories). Membranes were probed
using antibodies including a rabbit polyclonal anti-phospho-Gsk3β (Ser9; 9336, Cell Signaling),
a rabbit monoclonal anti-Gsk3β (9315; Cell Signaling), a rabbit polyclonal anti-AXIN2
(SAB3500619; Sigma Aldrich), a rabbit monoclonal anti-non-phospho (active) βcatenin(Ser33/37/Thr31, 8814; Cell Signaling), a rabbit polyclonal β-catenin (sc7199; Santa Cruz),
a monoclonal β-actin (sc47778; Santa Cruz) and a goat secondary antibody against rabbit (7074;
Cell Signaling). Immunoreactive bands were visualized using Supersignal West Dura Extended
Duration Substrate (Thermo Scientific) and autoradiography film (Lab Scientific Inc) in
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accordance with the manufacturer’s instructions. ImageJ was used to densitometrically quantify
band densities.

4.3.8. Statistical analysis
Results are presented as means ± S.D. Student’s t-test was used to analyze differences between
groups. Differences were considered significant at p values less than 0.05.

4.4 Results

4.4.1. Expression of Wnt signaling components in Vector and HMWTg joints
Previously, we have shown that HMWTg mice develop osteoarthropathy as early as 2 months of
age and in order to determine if Wnt signaling may be contributing to this phenotype, we
examined 2-month-old male Vector and HMWTg knees for protein and gene expression of
components of the Wnt signaling pathway. Sclerostin (SOST), a Wnt inhibitor, was not present
in HMWTg knees, however, Vector mice had SOST expression in the subchondral bone.
Phosphorylated LRP6 receptor protein was decreased in HMWTg articular cartilage, compared
to Vector cartilage, yet phosphorylated LRP5 was strongly expressed in HMWTg cartilage
compared to Vector. Ligands,WNT5A and WNT7B, were greatly increased in HMWTg cartilage
compared to Vector. Also, phosphorylated inactive GSK3β and Lymphoid Enhancer Binding
Factor 1 (LEF1), both downstream components of canonical Wnt signaling, had strong
expression in HMWTg compared to Vector articular cartilage (Fig. 1A). To determine if
specifically canonical Wnt signaling, in which β-catenin does not become degraded, was
upregulated in HMWTg joints, we examined non-phosphorylated β-catenin by
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immunohistochemistry and expression was only present in HMWTg cartilage and not in Vector
knees (Fig. 1B). We then examined gene expression in whole joints from 2-month-old Vector
and HMWTg mice and similarly found that the Wnt inhibitors Sost and Dickkopf WNT
Signaling Pathway Inhibitor (Dkk1), and receptor Lrp6 mRNA levels were significantly
decreased in HMWTg compared to Vector. Also, Wnt5a, Axin2, and Lef1 gene expression was
significantly increased in HMWTg joints compared to the Vector control (Fig. 1C).

4.4.2. Characterization of immature murine articular chondrocytes (iMACs) from Vector,
HMWTg, and LMWTg mice
To be able to study more directly how the chondrocyte phenotype and Wnt/β-catenin signaling is
modulated in Vector, HMWTg, and LMWTg mice, we microsurgically dissected articular
cartilage from postnatal mice (one litter/genotype/experiment) and studied in vitro in monolayer.
On day 7 in culture, chondrocytes reached confluence and were fixed and stained for alcian blue.
From four independent experiments chondrocytes from LMWTg consistently had slightly less
blue staining, whereas, HMWTg chondrocytes had more robust staining, indicating increased
glycosaminoglycan content compared to Vector or LMWTg (Fig. 2A). Similarly, alkaline
phosphatase staining was markedly less in LMWTg chondrocytes and staining in HMWTg
chondrocytes was highly increased, indicating enhanced hypertrophic differentiation (Fig. 2A).
Next, RNA was isolated from cultures on day 7 and qPCR analysis was used to determine
expression levels of genes involved in FGF and Wnt signaling and OA pathogenesis. Of
importance, Fgf23, Adamts5, Interleukin 1 beta (Il1-β), Wnt7b, Wnt16, and Wisp1 were
significantly increased in HMWTg chondrocytes. Also, FGF23, Il1-β, and Wnt7b were
significantly decreased in LMWTg chondrocytes (Fig. 2B). Table 3 lists any genes that had
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significant difference in mRNA level between genotypes and it was determined that HMW
chondrocytes had increased Fgf18 levels but not as elevated as LMW chondrocytes. Also,
FGFR3 expression was decreased in HMW chondrocytes but FGFR3c was increased in HMW
compared to Vector. Degradative enzyme, Mmp9, expression level was significantly increased in
HMW compared to LMW. Transcription factors Sex determining region Y box 9 (Sox9), ColX,
Indian hedgehog (Ihh), and Sclerostin domain containing 1 (Sostdc1) expression was
significantly less in LMW compared to Vector. While Col1 levels were increased in HMW, NK3
Homeobox 2 (Nkx3.2) and Wnt10b were decreased compared to Vector. To further determine if
Wnt signaling is modulated in these chondrocytes we examined phospho-GSK3β protein
expression by Western blot. From three independent experiments it was determined that
HMWTg had a statistically significant increase in phospho-GSK3β (Fig. 2C), indicating that
there is more inactive GSK3β, allowing less degradation of β-catenin and subsequent enhanced
transcription of β-catenin target genes.

4.4.3. Inhibition of Wnt/β-catenin on chondrocyte homeostasis
In order to determine if canonical Wnt signaling is contributing to the enhanced chondrocyte
differentiation and hypertrophy and OA in HMWTg cells, we treated cultures with IWR-1, a
potent Wnt inhibitor that stabilizes Axin2, a member of the β-catenin destruction complex,
ultimately leading to the degradation of β-catenin (96). This stabilization of Axin2 was
confirmed by increased Axin2 protein expression by Western blot in Vector, HMWTg, and
LMWTg groups compared to their Vehicle-treated controls (Fig. 3A). Consequently, active βcatenin versus total β-catenin was decreased after IWR-1 treatment for all genotypes as
determined by Western blot and the initial increase in active β-catenin in HMWTg Vehicle-
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treated compared to Vector and LMWTg was observed (Fig. 3A). IWR-1 treatment of
chondrocytes caused a decrease in both alcian blue and alkaline phosphatase staining in HMWTg
cultures, which appeared similar to that of Vector and LMWTg Vehicle-treated groups.
However, IWR treatment did not affect the staining in Vector or LMWTg cultures (Fig. 3B).
Furthermore, IWR-1 markedly reduced mRNA expression of the initially high Fgf23 expression
in HMWTg chondrocytes, yet somewhat increased expression in Vector and LMWTg. Adamts5
elevated expression was rescued in HMWTg after IWR-1 treatment. Though Axin2 gene
expression was significantly increased in HMWTg Vehicle-treated chondrocytes compared to the
Vector Vehicle-treated, mRNA levels were not significantly altered following IWR-1 treatment
compared to each group’s Vehicle-treated controls. qPCR also showed enhanced Wnt7b
expression in HMWTg, which was reduced after IWR-1 treatment (Fig. 3C).

4.4.4. Effects of long-term FGF23Ab treatment on joint homeostasis in Vector and HMWTg
Since HMWTg knees and chondrocytes have an OA phenotype and increased FGF23 expression,
and FGF23 has been found to promote chondrocyte hypertrophy and differentiation (47), we
assessed whether neutralization of FGF23 could rescue the OA phenotype in HMWTg mice. As
shown by digital radiography the flattened tibial plateau and narrowing of the joint space in the
HMWTg Vehicle-treated group was rescued following FGF23Ab treatment (Fig. 4A). 3D
renderings show abnormal contour and erosion of the subchondral surface in the HMWTg
Vehicle-treated group, while FGF23Ab treatment resulted in a phenotype resembling that of the
Vector groups (Fig. 4B). Sagittal microCT images reveal irregular shape and thinning of the
subchondral bone with decreased trabeculae number and thickness within the epiphyses of
HMWTg Vehicle-treated knees, which was rescued following FGF23Ab injections (Fig. 4B).
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Specifically, HMWTg Vehicle-treated femoral epiphyses had altered trabecular architecture
indicative of early OA and 3D morphometric parameters calculated from microCT results of the
epiphyses indicated increased BV/TV, trabecular thickness and number, and decreased trabecular
spacing, compared to Vector Vehicle-treated epiphyses, which were partially normalized with
FGF23Ab treatment (Fig. 4C). Finally, increased hypertrophic OA gene markers found in
mRNA from HMWTg Vehicle-treated joints showed rescue after FGF23Ab treatment, which
included ColX, Mmp13, and Mmp9 (Fig. 4D). Protein expression of MMP13 and MMP9 was
strongly expressed in HMWTg Vehicle-treated cartilage, but not present in either Vector group
or HMWTg FGF23Ab-treated mice (Fig. 4F&G). Articular cartilage thickness was decreased in
HMWTg Vehicle-treated mice, similar to what was observed in our initial study (17) and was
then restored to the cartilage thickness of Vector mice in the HMWTg FGF23Ab-treated group
(Fig. 4E).

4.5 Discussion
This study examined modulation of FGF23 and canonical Wnt signaling in chondrocytes
obtained from mice that overexpress the high molecular weight isoforms of FGF2 and develop
OA. We found the following: (i) Joints of HMWTg mice, which have elevated FGF23
expression, had decreased Sost, Dkk1, and Lrp6 expression and increased Wnt7b, Wnt5a, Lrp5,
Axin2, Gsk3β, Lef1, and nuclear β-catenin levels. (ii) Chondrocytes of HMWTg mice had
accelerated differentiation and increased Fgf23, Adamts5, Il-1β, Wnt7b, Wnt16, Wisp1, and
phospho-Gsk3β. (iii) Inhibition of canonical Wnt signaling rescued hypertrophy and Fgf23,
Adamts5, and Wnt7b levels in HMWTg chondrocytes. (iv) The OA phenotype in HMWTg mice
can be partially rescued by neutralizing FGF23Ab treatment in vivo. Collectively, this data
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suggests that FGF23 modulates Wnt/β-catenin signaling promoting chondrocyte differentiation,
resulting in OA (Fig. 5).
Disruption of cartilage homeostasis is a primary reason of OA pathogenesis and is
initiated by varying physical or genetic factors, leading to an imbalance of anabolic and catabolic
factors, resulting in modulation of various biochemical pathways (7). Although we have
previously published that HMWTg mice, phenocopy both Hyp mouse and XLH, spontaneously
develop degenerative joint disease, the molecular mechanism driving this OA phenotype was
unclear (83), but in this study we show for the first time that FGF23 is a catabolic regulator of
Wnt/β-catenin signaling-mediated OA cartilage destruction. In vivo we observed increased
FGF23 and FGFR1 expression in HMWTg cartilage (83) and it is well established that FGF23
stimulates hypertrophy, and signaling through FGFR1 leads to a cascade of events that are
catabolic in articular chondrocytes (25). Also, FGFR signaling has been shown to increase
Wnt/β-catenin signaling in chondrocytes (59). Though Wnt signaling can have differing effects
on cartilage homeostasis (51,52), our findings are consistent with its negative role. We found that
inhibitors, Sost and Dkk1, were decreased in HMWTg joints, essentially allowing activation of
the Wnt pathway, and similarly it was found that increased Sost and Dkk1 levels protect against
cartilage degradation in OA in mice (57,58). Interestingly, we observed an increase in LRP5 with
a decrease in LRP6 in HMWTg, which further strengthens the argument that these receptors can
have distinct functions, and that LRP5 (but not LRP6) is essential for Wnt-induced cartilage
destruction by regulating production of MMPs (53), as we have also shown increased MMPs
expression in vivo and in vitro.
While aberrant noncanonical Wnt signaling can contribute to OA (49,50) and we
observed increased Wnt5a expression in HMWTg, which is most often associated with the
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noncanonical pathway, there is evidence that suggests that Wnt5a activates the canonical
pathway in the presence of LRP5 (97), which was also increased in our study. Furthermore, we
observed increased Wnt7b expression in HMWTg chondrocytes, which is an exclusively
canonical ligand (55), increased inactivation of Gsk3β, increased LEF1, Wisp1, and nuclear βcatenin, which indicates that β-catenin is stabilized and translocated to the nucleus, which is due
to enhanced canonical signaling.
Since various areas within an osteoarthritic joint contribute to the disease, it is of great
importance that we were able to identify the articular chondrocyte as the component of the knee
that may be responsible for the pathogenesis of OA observed in HMWTg mice. Even though in
the Hyp mouse (which has increased Wnt signaling in varying tissues (61,62)) it was determined
that cellular changes occur within articular cartilage that contribute to the osteoarthropathy, these
mice and humans with XLH also develop OA-like changes in the subchondral bone and tendons
(44) so it was unclear what tissue was driving the phenotype. Isolating articular chondrocytes
from pups that were only 5 days old and growing for just 7 days in undifferentiating media
mimicked the in vivo results of HMWTg cartilage, which included increased FGF23/catabolic
factor expression, mineralization, and chondrogenic hypertrophy (83). Firstly, alcian blue and
alkaline phosphatase (mineralization) staining was strongest in HMWTg and lowest in LMWTg
cultures, indicating that HMWTg chondrocytes have accelerated chondrogenic differentiation.
Col1 was statistically significantly increased in HMWTg cultures and ColX was decreased in
LMWTg cultures, which are markers for fully differentiated chondrocytes (98). Also, LMWTg
cultures had a significant reduction in Sox 9, which acts further at each stage in chondrogenic
differentiation (99) and Ihh, which simulates chondrogenic cell differentiation (100), while
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HMWTg cultures had a decrease in Nkx3.2, which has been found to decrease as chondrocytes
mature and become more hypertrophic (101).
Although FGFR3c was increased in HMWTg cultures, total FGFR3 was significantly
decreased, which is the primary receptor of FGF18 (which was greatly increased in LMWTg)
and downstream signaling promotes anabolic activity in chondrocytes (27). Just as we had
previously observed in vivo, HMWTg chondrocytes are unable to maintain their normally
quiescent nature resulting in rapid chondrogenesis, whereas, LMWTg chondrocytes appear to
have slower differentiation potential resulting in protection from OA. Further studies will be
needed to fully elucidate the mechanism by which the LMW FGF2 isoform confers a
chondroprotective effect.
The OA phenotype in HMWTg but not LMWTg chondrocytes is due to enhanced
canonical Wnt signaling mediated by FGF23 since in addition to increased FGF23 mRNA levels,
HMWTg chondrocytes had increased expression of other components of the Wnt/β-catenin
signaling pathway. Once the cells were treated with a canonical Wnt inhibitor, IWR-1, which
stabilizes Axin2 allowing more degradation of cytoplasmic β-catenin, the hypertrophic
phenotype was rescued in HMWTg chondrocytes. Also, Adamts5 expression was decreased to
levels found in Vector or LMWTg chondrocytes following treatment in HMWTg cultures.
Interestingly, FGF23 and Wnt7b elevated expression in HMWTg chondrocytes was markedly
reduced after IWR-1 treatment. This decrease in FGF23 expression may be due to inhibition of
active β-catenin, which has been found to enhance FGF23 promoter activity (61). Similarly, in
the presence of higher levels of FGF23 we showed there was increased Wnt7b expression, so if
FGF23 is unable to be transcribed we would expect to see a decrease in Wnt7 levels. However,
future studies are necessary to determine how FGF23 signaling regulates Wnt7b expression.
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Additionally, this study identified a potential therapeutic approach to partially rescue
osteoarthropathy in HMWTg mice by long-term treatment with a neutralizing FGF23Ab, which
has previously been reported to ameliorate rickets, osteomalacia, and hypophosphatemia in the
Hyp mouse (102) and human subjects with XLH (103). This is a novel finding in that there are
no disease modifying drugs to treat degenerative joint disease and the effect of FGF23Ab
treatment on the OA phenotype in the earlier studies was not examined (102,103). Specifically,
the microarchitecture of the subchondral bone was able to be restored to that of the Vector
control after FGF23Ab treatment. Notably, ColX and MMPs expression was reduced in HMWTg
+ FGF23Ab treated knees, which indicates that neutralizing FGF23 is restoring chondrocyte
function, since these degradative/hypertrophic markers are expressed by osteoarthritic articular
cartilage, as was observed by immunohistochemistry in the HMWTg + Vector group. The rescue
of cartilage thickness also indicates the impact of the antibody on chondrocytes.
Herein we provide evidence suggesting that FGF23 catabolically influences OA
pathophysiology through canonical Wnt/β-catenin signaling in chondrocytes. These results
provide new insight into the role of FGF23 in the pathogenesis of cartilage degradation in the
context of XLH and identify Wnt/β-catenin FGF23-mediated signaling as a candidate pathway to
be targeted in the treatment or prevention of OA.
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4.6 Figures

Figure 4.6.1. Expression of components of the Wnt pathway in knees of 2-month-old male
Vector and HMWTg mice. A, Representative immunohistochemical staining shows no protein
expression of SOST in the subchondral bone of HMWTg compared to Vector (arrowheads) and
decreased phospho-LRP6 expression in articular cartilage (dashed arrows). Arrows indicate
increased expression of phospho-LRP5, WNT5A, WNT7B, phospho-GSK3, and LEF1 in
HMWTg cartilage compared to Vector. Magnification=10X, n=3/group. B, Representative
images show evidence of active -catenin protein expression in HMWTg cartilage (arrows).
Magnification=20X, n=3/group. C, qPCR analysis shows decreased Sost, Dkk1, and Lrp6 and
increased Wnt5a, Axin2, and Lef1 mRNA levels of HMWTg joints compared to Vector. Values
are the means ± SD. *P <0.05**P <0.01, ***P <0.001, n=7-8/group.
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Figure 4.6.2. Basal characterization of primary immature murine articular chondrocytes
cultured for 7 days. A, Alcian blue staining shows enhanced matrix proteoglycan production by
HMWTg compared to Vector and LMWTg. Alkaline phosphatase staining was increased in
HMWTg chondrocytes compared to Vector and LMWTg. The data is representative of 4
independent experiments. Magnification = 4X. B, mRNA expression revealed modulated gene
expression between genotypes by qPCR analysis. C, Phospho-GSK3 protein expression was
significantly higher in HMWTg chondrocytes compared to Vector. The mRNA expression and
protein levels were expressed as relative (fold changes) to the expression of the Vector group.
Values are the means ± SD for 3 independent experiments. *:compared with Vector p< .05.
#:compared with HMWTg p< .05.
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Figure 4.6.3. Effect of IWR on primary articular chondrocytes from HMWTg, LMWTg,
and Vector mice. A, Western blots showed increased Axin2 protein expression after treatment
with IWR for 48 hours. Active -catenin protein expression was greatest in the HMWTg-Vehicle
treated group and was decreased after IWR treatment in all genotypes. Statistical analysis of
Western blots of Axin2/Actin and Active -catenin/Total -catenin from 3 independent
experiments is represented as the means ± SD. B, Alcian blue staining showed a decrease in
matrix proteoglycan production after IWR treatment in HMWTg chondrocytes compared to
Vehicle-treated, while Vector and LMWTg IWR-treated cultures retained their Vehicle-treated
phenotype. Following IWR treatment, alkaline phosphatase staining was decreased in HMWTg

104

with no effect on Vector and LMWTg chondrocytes. Magnification = 4X. C, IWR treatment
modulated mRNA expression and rescued some gene expression in HMWTg cultures as
indicated in the qPCR analysis. The mRNA expression is expressed as relative (fold changes) to
the expression of the Vector group. Values are the means ± SD for 3 independent experiments.
p< .05. ¢:compared with Vector + IWR p< .05. $:compared
with HMWTg + Vehicle p< .05. #:compared with HMWTg + IWR p< .05.
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Figure 4.6.4. Effect of FGF23Ab on joints of HMWTg and Vector female mice. A, Digital
radiographs show flattening of the tibial plateau and joint space narrowing (bracket) in Vehicletreated HMWTg mice, while FGF23Ab-treated HMWTg knees have a similar phenotype to both
Vector control groups. B, 3D reconstructive images show pitting and erosion of the surface
(yellow arrows) in the HMWTg + Vehicle knees compared to the smooth contour of all other
groups. High-resolution microCT sagittal images of HMWTg + Vehicle display flattened tibia
(dashed arrow), thinning and abnormal morphology of subchondral bone (white arrow) and
decreased trabecular number and thickness in the femoral and tibial epiphyses. HMWTg +
Fgf23Ab phenotype resembles that of Vector + Vehicle and Vector + Fgf23Ab groups. C, 3D
morphometric parameters revealed a significant decrease in BV/TV, Tb.N, and Tb.Th and
increase in Tb.Sp in HMWTg + Vehicle femoral epiphyses compared with the Vector + Vehicle
group, while there is some rescue in the HMWTg + FGF23Ab knees. BV/TV, trabecular bone
volume; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Th; trabecular thickness. C,
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qPCR analysis of mRNA taken from the knees shows increased expression of ColX, Mmp13,
and Mmp9 in HMWTg + Vehicle mice, with some rescue in the HMWTg + FGF23Ab group. E,
Safranin-O staining show decreased articular cartilage thickness (bracket) in HMWTg + Vehicle,
which is restored in HMWTg + FGF23Ab. F-G, Representative immunohistochemical staining
show increased MMP13 and MMP9 expression (arrows) in femoral articular cartilage of
HMWTg + Vehicle, which is decreased in HMWTg + FGF23Ab. N=3-4/group. Values are the
means ± SD.

p< .05. ¢:compared with Vector + FGF23Ab

p< .05. $:compared with HMWTg + Vehicle p< .05. #:compared with HMWTg + FGF23Ab p<
.05.
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Figure 4.6.5. Schematic model in which HMW FGF2-mediated FGF23 stimulation of
chondrocyte differentiation and osteoarthritis is partially through modulation of the
Wnt/β-catenin pathway. Overexpression of HMW FGF2 enhances FGF23 expression which
results in enhanced Wnt7b and phospho-Lrp5 and reduced Sost and Dkk1 expression. Increased
inactive phosphorylated Gsk3β and Axin2 allow β-catenin to accumulate and be translocated to
the nucleus where it binds LEF/TCF promoting transcription of OA and chondrocyte
hypertrophic genes. When HMW FGF2 is not overexpressed there is less FGF23 expression
resulting in reduced Wnt7b and increased Sost and Dkk1 expression, ultimately leading to
reduced Wnt/β-catenin signaling and less chondrocyte differentiation.
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Table 4.6.1. Antibody Table
Peptide/Prot
ein Target

Name of
Antibody

SOST

Mouse
SOST/Sclerostin
antibody

LRP6

LRP6 (SER1490)
polyclonal
antibody

LRP5

Species Raised
(Monoclonal/Polyclonal)

Dilution

Goat;polyclonal

1:100

Bioss, bs-3253R

Rabbit;polyclonal

1:100

Anti-LRP5
(phosphoT1492)
antibody

Abcam,
ab203306

Rabbit;polyclonal

1:100

WNT5A

Mouse/Rat Wnt5a antibody

R & D Systems,
AF645

Goat;polyclonal

1:50

WNT7B

Wnt7b antibody

GeneTex,
GTX114881

Rabbit;polyclonal

1:100

Anti-GSK3 beta
(phospho Y216)
antibody

Abcam, 75745

Rabbit;polyclonal

1:50

GSK3β

Manufacturer/
Catalog
Number
R & D Systems,
AF1589

LEF1

Anti-LEF1 (AB1) Sigma-Aldrich,
antibody
AV32404

Rabbit;polyclonal

1:50

β-catenin

Non-phospho
(Active) βCatenin
(Ser33/37/Thr41)
(D13A1) Rabbit
mAb
Anti-MMP13
antibody

Cell Signaling,
8814

Rabbit;monoclonal

1:50

Abcam,
ab39012

Rabbit;polyconal

1:100

MMP-9 antibody
(C-20)

Santa Cruz,
sc6840

Goat;polyclonal

1:100

MMP13

MMP9
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Table 4.6.2. Primers used in qRT-PCR.
Gene

Forward

Reverse

β-actin

5’-atggctggggtgttgaaggt-3’

5’-atctggcaccacaccttctacaa-3’

Axin2

5’-aacctatgcccgtttcctcta-3’

5’-gagtgtaaagacttggtccacc-3’

Sost

5’-ggaatgatgccacagaggtcat-3’

5’-cccggttcatggtctggtt-3’

Sostdc1

5’-actggatcggaggaggctatgg-3’

5’-tgtggctggactcgttgtgc-3’

Dkk1

5’-gggagttctctatgagggcg-3’

5’-aagggtagggctggtagttg-3’

Wisp1

5’-gtggacatccaactacacatcaa-3’

5’-aagttcgtggcctcctctg-3’

Wnt5a

5’-ctccttcgcccaggttgttatag-3’

5’-tgtcttcgcaccttctccaatg-3’

Wnt7b

5’-ttctggaggaccgcatgaa-3’

5’-ggtccagcaagttttggtggta-3’

Wnt16

5’-agtgcaggcaacatgaccg-3’

5’-ccacatgccgtactggacatc-3’

Wnt10b

5’- ttctctcgggatttcttggattc-3’

5’- tgcacttccgcttcaggttttc-3’

Lrp6

5’-ggtgtcaaagaagcctctgc-3’

5’-acctcaatgcgatttgttcc-3’

Lef1

5’-gccaccgatgagatgatccc-3’

5’-ttgatgtcggctaagtcgcc-3’

Mmp-13

5’-ctttggcttagaggtgactgg-3’

5’-aggcactccacatcttggttt-3’

Mmp-9

5’-gcgtcgtgatccccacttac-3’

5’-caggccgaataggagcgtc-3’

Adamts5

5’-cctgcccacccaatggtaaa-3’

5’-ccacatagtagcctgtgccc-3’

Col10a1

5’-gggaccccaaggacctaaag-3’

5’-gcccaactagacctatctcacct-3’

Col1a1

5’-ggtcctcgtggtgctgct-3’

5’-acctttgcccccttctttg-3’

Fgf23

5’-acttgtcgcagaagcatc-3’

5’-gtgggcgaacagtgtagaa-3’

Fgf18

5’-aaggagtgcgtgttcattgag-3’

5’-agcccacataccaaccagagt-3’

FGFR3

5’-ccggctgacacttggtaag-3’

5’-cttgtcgatgccaatagcttct-3’

FGFR3c

5’-gttctctctttgtagactgc-3’

5’-agtacctggcagcacca-3’

IL-1β

5’-gcaactgttcctgaactcaact-3’

5’-atcttttggggtccgtcaact-3’

Ihh

5’-ggcgctacgaaggcaagat-3’

5’-cttgaagatgatgtcgggattgt-3’

Sox9

5’-agtacccgcatctgcacaac-3’

5’-acgaagggtctcttctcgct-3’

Nkx3.2

5’-aaagtggccgtcaaggtgct-3’

5’-agcccgggagacagtagtaa-3’
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Table 4.6.3. Relative fold change of gene expression of Vector, HMWTg, and
LMWTg iMACs
Gene

Vector

HMWTg

LMWTg

1.94 ± 0.70

Vector vs.
HMWTg
p-value
0.044

Vector vs.
LMWTg
p-value
0.009

HMWTg vs.
LMWTg
p-value
0.034

Fgf18

1.02 ± 0.08

1.21 ± 0.19

FGFR3

0.97 ± 0.10

0.48 ± 0.21

1.35 ± 1.25

0.000

0.477

0.126

FGFR3c

1.10 ± 0.13

1.48 ± 0.30

0.98 ± 1.00

0.017

0.766

0.263

Mmp9

1.02 ± 0.10

2.57 ± 1.98

0.65 ± 0.43

0.086

0.067

0.043

Sox9

0.99 ± 0.08

0.81 ± 0.21

0.72 ± 0.27

0.076

0.041

0.524

ColX

1.03 ± 0.05

0.70 ± 0.40

0.83 ± 0.22

0.071

0.049

0.502

Col1

0.97 ± 0.11

1.93 ± 0.52

1.80 ± 0.77

0.001

0.026

0.751

Ihh

0.98 ± 0.04

1.24 ± 1.07

0.54 ± 0.26

0.571

0.002

0.150

Nkx3.2

1.00 ± 0.04

0.60 ± 0.12

0.90 ± 0.21

0.000

0.251

0.012

Wnt10b

0.96 ± 0.18

0.70 ± 0.17

0.93 ± 0.34

0.030

0.885

0.160

Sostdc1

1.09 ± 0.24

0.96 ± 0.64

0.51 ± 0.26

0.642

0.002

0.141

Dkk1

1.33 ± 0.37

2.50 ± 1.26

1.79 ± 0.32

0.056

0.044

0.216
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Chapter 5
Significance, Future Directions, and Conclusion
5.1 Significance
Though FGF2 has been well studied regarding its involvement in cartilage homeostasis
and OA pathogenesis, and previous research suggests both a catabolic and anabolic role (25-28),
the mechanism by which it causes these effects remained unknown. Firstly, we provide evidence
that the two distinct isoforms of FGF2 play differing roles in OA and cartilage maintenance, an
idea that had previously never been addressed. In doing so, we demonstrated that the contrasting
effect of FGF2 on cartilage may be due to its isoforms, in that the high molecular weight isoform
exerts a negative impact while the low molecular weight isoform is chondroprotective.
Furthermore, FGF23 was known to be destructive in chondrocytes (45,46) and we were able to,
for the first time, identify a potential mechanism by which this occurs, showing its regulation in
Wnt/β signaling-mediated OA cartilage degradation. Concurrently, we add more evidence to the
damaging potential of canonical Wnt signaling, rather than protective, as some former
publications have reported (52). Additionally, it is of great importance that we were able to
identify the articular chondrocyte as the component of the knee that is responsible for the
pathogenesis of OA in our model, since various areas within an osteoarthritic joint can contribute
to the disease. The chondrocyte in vitro studies recognized a possible pathway (canonical Wnt
signaling) that could be targeted to prevent or inhibit OA initiation and prevention. Also, this
study identified a potential therapeutic approach that partially rescued OA in vivo using a
neutralizing FGF23Ab, a novel finding in that there are no disease modifying drugs to treat
degenerative joint disease.
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5.2 Future Directions
Although the current project revealed valuable information about FGF2 in the pathogeny
of OA, future studies will still be needed to further clarify some of our results. While the
mechanism by which HMW FGF2 negatively affects cartilage was determined, the biochemical
pathway(s) involved in how the LMW FGF2 isoform positively regulates cartilage remains
unknown. Our studies suggest that LMW FGF2 may enhances FGF18 and signal through
FGFR3, which promotes an anabolic signaling cascade (27), but a more comprehensive analysis
is needed. Also, this present work focused on articular chondrocytes and FGF2 should be studied
in other cells types of the joint, including subchondral osteoblasts and osteoclasts or
synoviocytes. Similarly, mouse models with tissue-specific deletions in cartilage or bone would
be useful to delete full-length FGF2 or the selective isoform, since the knockout mouse models
that were used had constitutive deletions. Even though it was determined that increased FGF23
elevated Wnt7b levels, future studies are needed to understand how FGF23 regulates Wnt7b.

5.3 Conclusion
Broadly, the current research project demonstrated the following: (i) Mice overexpressing
HMW FGF2 develop OA with an increase in FGF23 and FGFR1 in cartilage, while mice
overexpressing LMW FGF2 do not develop OA. (ii) Neutralization of FGF23 attenuates some
signs of OA in HMWTg. (iii) Mice only expressing HMW FGF2 and not LMW FGF2 develop
OA similar to that observed in mice deficient in full-length FGF2, whereas mice expressing only
LMW FGF2 are protected from age-related and mechanically-induced OA. (iv) Joints and
chondrocytes of HMWTg have increased expression of components of canonical Wnt signaling
leading to accelerated hypertrophy/differentiation, which is rescued by inhibiting Wnt.
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Specifically, HMW FGF2 modulates FGF23/FGFR1/Wnt/β-catenin signaling-mediated
OA in chondrocytes. Overall, this work offers novel insight into the role of FGF2 in the
pathophysiology of cartilage degradation in not only the context of XLH but overall OA disease,
and specifies a candidate pathway to be targeted in the treatment or prevention of OA.
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